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1.3 SUMMARY OF THE THESIS   
Variants in POLG, the gene encoding the catalytic subunit of DNA-polymerase gamma 
(polγ), the enzyme that replicates and repairs the mitochondrial genome, are among the 
most common causes of inherited mitochondrial disease. The clinical phenotypes of 
POLG disease are overlapping and extremely heterogeneous, making early clinical 
recognition challenging. The aim of my PhD project was to study the clinical spectrum 
and natural course of POLG disease in a large cohort of patients in order to provide a 
reliable clinical classification that was useful in both paediatric and adult populations, 
and to identify robust diagnostic and prognostic biomarkers which could facilitate early 
diagnosis and/or predict the prognosis. 
Multinational, retrospective studies of individuals recruited from 13 centres in seven 
European countries (Norway, Sweden, Denmark, Finland, Netherlands, Spain and the 
United Kingdom) were performed. Clinical, laboratory, neurophysiological, neuro-
imaging, and genetic data were systematically collected using a standardized electronic, 
web-based clinical record form. 
The results of this project provide clear evidence that the clinical features of POLG 
disease are a continuum, i.e. the same spectrum of symptoms/features is found in all age 
groups. This allowed us to classify POLG disease more simply than the earlier attempts 
which only generated a plethora of syndromes with overlapping features. 
The project provides also an extensive phenotypic characterisation of patients with early 
onset disease and demonstrated the breadth of clinical manifestations and natural history 
of the disease in this age group. Highlighting the existence of POLG disease without 
seizures will improve diagnosis of those with early onset disease. 
The study cohort included individuals with disease onset from birth to late adulthood; 
this enabled us to study the clinical spectrum of the disease through all the ages. We 
could identify clear phenotypic and prognostic differences by grouping the patients 
simply using age of onset to: early onset, juvenile and adult, and late onset disease. We 
believe that our simplified classification will facilitate early clinical recognition, guide 




Further, the results of this project showed that  POLG disease is associated with blood 
brain barrier dysfunction and that the presence of raised cerebrospinal fluid 
protein/albumin can be used as a biomarker both for early diagnosis and to predict those 
who will be at risk to develop epilepsy. Moreover, the project revealed, for the first time, 
that anaemia is a feature of POLG disease, and the presence of anaemia is associated 
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1.5 LIST OF ABBREVIATIONS   
AD: Autosomal dominant. 
ADP: Adenosine diphosphate. 
adPEO: autosomal dominant chronic progressive external ophthalmoplegia.  
AED: Antiepileptic drug. 
ALAT: Alanine aminotransferase.  
AR: Autosomal recessive. 
ASAT: Aspartate aminotransferase.   
ATP: Adenosine triphosphate.  
BBB: Blood brain barrier.  
CFL: Cortical focal lesion. 
CNS: Central nervous system. 
CSF:  Cerebrospinal fluid.  
DNA: Deoxyribonucleic acid. 
dNTP: Deoxyribonucleotide triphosphate. 
eCRF: electronic-Case Report Form. 
EEG: Electroencephalogram.  
EPC:  Epilepsia partialis continua. 
FAD: Flavin adenine dinucleotide. 
FADH2: Reduced flavin adenine dinucleotide.  
FDG-PET: 18F fluoro-deoxy-glucose positron emission tomography. 
FGF21: Fibroblast growth factor 21. 




MCHS: Myocerebrohepatopathy spectrum. 
MELAS: Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes.  
MEMSA: Myoclonic epilepsy, myopathy, sensory ataxia. 
MNGIE: Mitochondrial neurogastro-intestinal encephalomyopathy. 
MRI: Magnetic resonance imaging. 
MRS: Magnetic resonance spectroscopy. 
mtDNA: mitochondrial DNA.  
mtSSB: mitochondrial single-strand binding protein.  
NAD+: Nicotinamide adenine dinucleotide. 
NADH: Reduced nicotinamide adenine dinucleotide 
nDNA: Nuclear DNA. 
NF-L: Neurofilament light chain.  
OXPHOS: Oxidative phosphorylation. 
PEO: Progressive external ophthalmoplegia.  
POLG: The catalytic subunit of Pol γ. 
Pol γ: Polymerase gamma. 
RBC: Red blood cell. 
RC:  Respiratory chain.  
SE: Status epilepticus. 







2. INTRODUCTION  
2.1  HISTORICAL OVERVIEW   
Mitochondria were first described as intracellular structures with vital cellular functions 
by Altmann in 1890. The name mitochondria was first introduced in 1898 and originates 
from The Greek “mitos” (threads) and “chondros” (granules)(1). The early recognition 
of the nature of cell respiration started in the 1910s and the reconstitution of the 
respiratory chain was first described early in the 1960s (1-3). Mitochondria were for the 
first time linked to human disease in 1962 by the Swedish endocrinologist Rolf Luft 
who described a young woman with hyper-metabolic syndrome and biochemical and 
histological findings suggesting mitochondrial dysfunction (4). In 1963 it was shown 
that mitochondria have their own genome, mitochondrial DNA (mtDNA) (5, 6).  
Initially, it was thought that variants in mtDNA were the most common cause of human 
mitochondrial disease (7, 8). However, it was subsequently shown that the respiratory 
chain  is under dual genetic control, mtDNA and nuclear DNA (nDNA), and a new class 
of mitochondrial disease emerged: disorders of nuclear-mitochondrial intergenomic 
cross talk (9), which is becoming the most common form of mitochondrial disease (10).    
Almost four decades have passed since the discovery that mtDNA is inherited 
exclusively from the maternal side (11) and mtDNA point mutations (12) or deletions 
(13) can cause human disease. Since then, a growing number of mtDNA defects and 
variants in nuclear genes encoding proteins essential for mitochondrial structure and 
function have been identified and associated with human disease both in paediatric and 
adult populations.  Advances in the laboratory diagnostic methods, including in recent 
years whole-exome sequencing, have enhanced this process. Approximately 1500 genes 
are currently known to encode the mitochondria-related proteins (14) and approximately 
300 of those are known to cause a disease (http://www.mitomap.org).  It is now well 
established that mitochondrial disorders due to variants in either mtDNA or nDNA 
genes are the most common inborn error of metabolism with an estimated prevalence of 




Mitochondria have received increasing attention in recent decades as evidenced by the 
expanding number of mitochondrial related publications compared to other organelles 
such as the nucleus, Golgi apparatus and endoplasmic reticulum (16) . This reflects the 
increasing relevance of mitochondrial disease in modern medicine.                 
Pathogenic variants in any of the mtDNA genes encoding for the 13 subunits of the 
oxidative phosphorylation (OXPHOS) complexes, the 22 mitochondrial tRNAs, two 
rRNAs, or in any of the nuclear genes encoding the rest of the approximately 1500 
proteins essential for mitochondrial structure and function, may result in mitochondrial 
dysfunction and disease. Clinically, affected individuals can present with a spectrum of 
heterogeneous phenotypes and disease onset at any time during their life span, and often 
with multi-organ involvement. However organs with high energy demand, such as the 
brain, heart  and the skeletal muscles, are the most vulnerable (17).     
Despite the advances in diagnostic methods and better understanding of mitochondrial 
biology, early clinical recognition of patients with mitochondrial disorders is still 
challenging, demonstrating the translational gap between the advances in science and 
clinical practice.  
 
2.2  MITOCHONDRIAL STRUCTURE AND FUNCTIONS  
Mitochondria are complex organelles present in the cytoplasm of almost all human cells, 
apart from mature erythrocytes. Each mitochondrion is enclosed by two highly 
specialized, phospholipid membranes known as the outer and the inner membranes. 
These create two separate compartments; the inter-membrane space and the matrix.  The 
outer mitochondrial membrane contains many porin molecules forming large aqueous 
channels which are freely permeable to all molecules of 5000 Daltons or less. These 
molecules can enter into the inter-membrane space, but most of them cannot proceed 
further into the matrix as the inner membrane is far less permeable and highly 
specialized, allowing only very small molecules to cross into the matrix. It is 
impermeable to most charged and hydrophilic substances such as ADP, ATP and 
pyruvate. The inner membrane is highly convoluted and forms specialised folds known 




higher capacity for ATP production.  The inner membrane also contains transport 
proteins to allow molecules to cross into the matrix, however, short chain fatty acids 
appear able to permeate the inner mitochondrial membrane without specialized transport 
mechanisms (18). The matrix contains mtDNA,  mitochondrial ribosomes, tRNA and 
proteins involved in many biochemical pathways, including the  Krebs cycle (also 
known as the citric acid cycle, or tricarboxylic acid), and beta-oxidation of fatty acids 
(19) (Figure 1).  
Figure 1. Mitochondrial structure.   
                                  
Mitochondria are cytoplasmic organelles with an inner and outer membrane, between 
which is the intermembrane space. The mitochondrial matrix lies within the inner 
membrane which is highly convoluted to form cristae. (Created with Biorender.com). 
 
Mitochondria are highly dynamic organelles and continuously change their size, shape 
and position, often forming networks through the opposing processes of fusion and 
fission (20). This machinery has an important quality control function as fusion 
contributes to mitochondrial maintenance, and fission allows the elimination of 
dysfunctional mitochondria. Dynamin-related GTPases on the outer mitochondrial 




are involved in the control of the fusion process, while the cytosolic soluble dynamin-
related protein 1 (DRP1) is involved in the fission process. (21, 22). 
The main function of the mitochondria is energy production in the form of ATP via the 
process of oxidative phosphorylation (OXPHOS) carried out by the respiratory chain, 
an enzyme pathway consisting of five multi-subunit protein-complexes located within 
the inner mitochondrial membrane. This pathway consists of the electron transport chain 
(complexes I -IV) and ATPase (complex V). Thirteen of the respiratory chain subunits 
are encoded by mtDNA while the remaining are encoded by nDNA (23).   
Mitochondria use both pyruvate and fatty acids as fuel. Glucose is metabolised to 
pyruvate by the process of glycolysis and then it is either converted to lactate or enters 
the mitochondrial matrix where it is oxidised by the pyruvate dehydrogenase (PDH) 
complex to form acetyl-CoA. This acetyl–CoA is then metabolized via the Krebs cycle, 
a process that generates NADH from NAD+ and FADH2 from FAD.   
The metabolism of fatty acids,  which  includes fatty acid oxidation or beta (β)-
oxidation, starts in the cytoplasm, where fatty acids are first converted into fatty acyl-
CoA molecules. The fatty acyl-CoA combines with carnitine to form a fatty acyl 
carnitine molecule, which is an important step in the transport of the fatty acid across 
the mitochondrial membrane. Once inside the mitochondrial matrix, the fatty acyl 
carnitine molecule is converted back into fatty acyl-CoA and then into acetyl-CoA by 
repeated cycles of β-oxidation. The newly formed acetyl-CoA enters the Krebs cycle. In 
contrast to long chain fatty acids (>C8) that are activated to acyl-CoA in the cytosol and 
transferred to the mitochondrial matrix by the carnitine shuttle, short and medium chain 
fatty acids, at least those of carbon atom number up to C8, permeate the inner 
mitochondrial membrane in the non-esterified form and are activated to their CoA-
derivatives in the mitochondrial matrix (18, 19).   
Complex I (NADH ubiquinone oxidoreductase) reoxidises NADH and the electrons 
released by this process shuttle to coenzyme Q10 (CoQ10, ubiquinone). Similarly, 
complex II (succinate ubiquinone oxidoreductase) oxides FADH2 and provides electrons 




I and II to complex III (ubiquinol cytochrome c oxidoreductase) which subsequently 
transfers the electrons from reduced CoQ10 (ubiquinol) to cytochrome c. These electrons 
will finally be donated to molecular oxygen (O2) via complex IV (cytochrome c oxidase) 
with the formation of water (H2O). During this process hydrogen cations (protons) are 
pumped from the mitochondrial matrix to the intermembranous space creating an 
electrochemical gradient across the mitochondrial inner membrane. The movement of 
these protons back into the matrix through complex V (ATP-synthase) provides the 
energy that generates ATP from ADP (24, 25) (figure 2).  
 
Figure 2: Mitochondrial metabolism and ATP production through the process of 
OXPHOS (Created with Biorender.com).  
 
 
                       






Besides energy production, mitochondria play an important role in several processes 
essential for maintaining cellular homeostasis including; iron-sulphur biogenesis, 
porphyrin and pyrimidine biosynthesis, calcium buffering and phospholipid metabolism 
(26, 27). Moreover, mitochondria are considered to be the major producers of reactive 
oxygen species (ROS), which are directly involved in programmed cell death 
(apoptosis) (28-30).   
2.3 THE GENETICS OF MITOCHONDRIAL DISEASE 
The mitochondrial respiratory chain is under dual genetic control. Components of four 
of the five complexes contain subunits encoded by mtDNA and nDNA. This means that 
the cross-talk between these two genomes is essential for the function of the respiratory 
chain (9). Primary mitochondrial disease can be caused by pathogenic variants in either 
mtDNA or nDNA, and manifests any mode of inheritance including maternal, autosomal 
recessive, autosomal dominant and X-linked  (31).   
2.3.1 Mitochondrial DNA  
A. What is mitochondrial DNA (mtDNA)? 
Mitochondria are the only organelles, other than the nucleus, that contain genetic 
information in the form of the mtDNA.  Human mtDNA is a 16.5 kb, double stranded, 
circular molecule encoding 37 genes (Figure 3). Thirteen of these genes encode 
OXPHOS subunits, the remaining 24 encode RNAs, two ribosomal RNAs (rRNA) and 
22 transfer RNAs (tRNA), that are needed for synthesis of mtDNA encoded proteins 
(32). Purine and pyrimidine content are unequally distributed between the two mtDNA-
strands resulting in a purine rich (heavy strand) and purine poor (light strand). MtDNA 
is a compact genome and contains little non-coding sequence apart from the 
displacement loop (D-Loop), which contains the promoters for transcription of both 







Figure 3: Human mtDNA.  
                
                  
Human mtDNA, double stranded, circular and consists of 16 569base pair. (Adapted 
and modified from https://en.wikipedia.org/wiki/Mitochondrial_DNA, created with 
biorender.com).  
 
B. Replication of mtDNA 
Replication of mtDNA is independent of the cell cycle (35, 36). The exact mechanism 
is still unclear and this has led to different theories: the asynchronous strand 
displacement and the strand coupled models (33, 34, 37). The POLG gene encodes the 
catalytic subunit of the mitochondrial DNA polymerase gamma (pol γ) which, together 
with two other proteins (a helicase called Twinkle and the mitochondrial single stranded 
binding protein (mtSSB), is required for mtDNA replication (38, 39). POLG also 
contains an exonuclease function that proofreads newly synthesised DNA and which is 





C. Inheritance of mtDNA   
Mitochondrial DNA is thought to be inherited exclusively from the mother (11). One 
case of paternal transmission of mtDNA mutation has been reported in a patient with 
myopathy (40) and paternal mtDNA sequences have been identified in next generation 
sequencing studies of healthy individuals (41).  
D. MtDNA is a multicopy genome 
Each cell contains multiple copies of mtDNA varying from approximately 100 in a  
sperm to more than 100,000 in a mature oocyte (42).  Normally, all mtDNA copies 
within a cell have the same sequence, a situation called homoplasmy. Pathogenic 
variants of mtDNA can affect some or all mtDNA copies. The situation in which there 
are two populations of mtDNA, one mutated and one wild-type is called heteroplasmy 
(43). Whether a phenotype manifests or not depends on there being a critical proportion 
of mutant mtDNA present in the cell; this is called the threshold, and this varies 
depending on the mutation and is usually between levels of  60-90 % mutated mtDNA 
(44).   
During the formation of the female germline, which occurs during early fetal 
development, the number of copies of mtDNA in the female primordial germ cell falls. 
The exact number is unclear but estimated to be in the order of 100-200 copies. 
Expansion of the copy number occurs during oocyte maturation such that the mature 
oocyte contains 100,000 copies. This contraction of the number of mtDNA copies with 
subsequent expansion is the basis of the bottleneck and the reason why mtDNA mutation 
heteroplasmy level can change dramatically from one generation to the next (45) (Figure 
4).  
Following fertilisation, varying amounts of wild-type and mutant mtDNA are randomly 
segregated to each of the daughter cells and since there is initially no replication, there 
is another decrease in mtDNA copy number per cell. Lastly, not all the cells in the 
blastocyst are destined to go into the fetus. Thus, if there is any cell to cell variation in 
the level of heteroplasmy, this can lead to different levels in the tissues that develop 




Figure 4: The mitochondrial genetic bottleneck. 
                                                         
The mitochondrial genetic bottleneck. Reduction followed by rapid replication of 
mtDNA copy number occurs during the process of oocyte maturation. This restriction 
and then amplification leads to variable level of mutant mtDNA being passed from one 
generation to the next. A: mature oocyte with high level of mutation (affected), B: 
mature oocyte with a medium level of mutation (mildly affected), C: mature oocyte with 
low level of mutation (probably not affected) (created with Biorender.com). 
 
E. MtDNA and disease  
The majority (80%) of primary mitochondrial disorders in adults and about 25% of 
mitochondrial disorders in the paediatric population are caused by pathogenic variants 
in mtDNA (46, 47) and more than 300 pathogenic mtDNA variants have been described 
(http://www.mitomap.org). Mutations in mtDNA can affect specific OXPHOS proteins 
or tRNA/rRNA leading to disruption of the synthesis of the mitochondrial proteins (48). 




mutations (49). The genotype-phenotype correlation is generally poor and this reflects 
several factors not least the different level of heteroplasmy.  
Large-scale mtDNA rearrangement syndromes: While the size of the deletions can vary 
from small to several kilobases, duplications are usually large.  Rearrangements usually 
affect several genes including protein coding and tRNA genes. Syndromes associated 
with the rearrangement of mtDNA include: Pearson syndrome (PS), which is an early 
onset and often life-threatening condition associated with transfusion-dependent 
sideroblastic anaemia and exocrine pancreatic dysfunction; Kearns-Sayre syndrome 
(KSS), a childhood or juvenile onset multi-systemic syndrome characterized by PEO, 
ptosis, mitochondrial myopathy with ragged red fibres, ataxia and life-threatening 
abnormalities of cardiac rhythm. Children surviving the pancytopenic phase of PS show 
evolution of clinical features into early onset KSS; Chronic Progressive External 
Ophthalmoplegia (CPEO) which may be an isolated paralysis of eye muscles and ptosis 
or associated with other extra-ocular manifestations such as myopathy, hearing loss, 
cataract (49-53).  
Point mutations of mtDNA. These can be  maternally  inherited or sporadic (54) and 
have been found in all mtDNA-encoding genes. Common syndromes include: 
Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes (MELAS) often 
caused by m.3243A>G in MT-TL1; Myoclonus Epilepsy with Ragged Red Fibre 
(MERRF) caused mainly by m.8344A>G in MT-TK; and Leber Heredity Optic 
Neuropathy (LHON) due to m.3460G>A in MT-ND1, m.11778G>A in MT-ND4 or 
m.14484T>C in MT-ND6. Mutations in the MT-ATP6 encoding  subunit 6 of the ATP 
synthase (complex V) typically give rise to maternally inherited Leigh syndrome or a 
milder phenotype characterized by neurogenic muscle weakness, ataxia, retinitis 
pigmentosa (NARP), depending on the level of heteroplasmy. Several other clinical 
manifestations are seen  with mutations in  cytochrome b of complex III and the mtDNA 






2.3.2 Nuclear DNA  
Pathogenic variants in the nuclear genome account for the majority of mitochondrial 
disorders. Approximately 1500 nuclear genes are necessary for proper mitochondrial 
function and maintenance (14). Only a small proportion of these encode structural 
subunits of the OXPHOS complexes (Table 1). The majority of nuclear genes encode 
factors involved in mtDNA maintenance, transcription and translation, or proteins 
involved in biosynthesis of lipids and cofactors, proteins involved in mitochondrial 
protein import and dynamics, assembly factors of OXPHOS complexes, enzymes 
involved in detoxification pathways or factors involved in mitochondrial dynamics, 
apoptosis, ion transport and protein import (23, 49, 55) .  
Table 1: Encoding of OXPHOS complexes 
Complex I II III IV V Total 
mtDNA encoding subunits 7 0 1 3 2 13 
nDNA encoding subunits 37 4 10 11 17 79 
Total 44 4 11 14 19 92 
 
Encoding of OXPHOS complexes. Mitochondrial OXPHOS complexes comprise more 
than 90 proteins, 13 of those encoded by mtDNA while the remaining subunits are 
encoded by nDNA.  
 
The most frequently affected nuclear gene causing mitochondrial disease is POLG, the 
main focus of this thesis and discussed in detail in the following sections. Other nuclear 
genes that are known to be associated with disorders of mtDNA stability, and which 









Table 2: Summary of the genes, other than POLG, associated with disorders of mtDNA 
maintenance and stability.  
 







Ataxia, encephalopathy, neuropathy, 
hepatopathy(56) 
  TFAM mtDNA replication Hepatopathy(57) 
  TK2 dNTP metabolism  Myopathy(58) 
  DGUOK dNTP metabolism  Encephalopathy, hepatopathy(59) 
  SUCLA2 dNTP metabolism  Encephalopathy, myopathy, ↑MMA(60) 
  SUCLG1 dNTP metabolism  Encephalopathy, myopathy, ↑MMA(61) 
  ABAT dNTP metabolism  Encephalopathy, myopathy, ↑MMA(62) 
  RRM2B dNTP metabolism  Encephalopathy, myopathy(63) 
  AGK dNTP metabolism  





















Myopathy, developmental delay, 
cataract,  hearing loss(67) 
  FBXL4 Mitochondrial dynamics  Encephalopathy, myopathy(68) 









  MGME1 mtDNA repair  Myopathy, PEO(71) 
  DNA2 mtDNA repair  Myopathy(72) 
  TK2 dNTP metabolism Ophthalmoplegia, myopathy(58)  















  SLC25A4 dNTP metabolism Myopathy(75) 
  MPV17 dNTP metabolism Neuropathy, myopathy(76) 






Spinocerebellar ataxia, progressive 
spasticity, dystonia(78)  
  SPG7 Mitochondrial dynamics Progressive spastic paraplegia(79)  
  MFN2 Mitochondrial dynamics Optic atrophy and neuropathy(80) 
Adulthood  TWNK  mtDNA replication AD ophthalmoplegia, myopathy(56)  
  TOP3A mtDNA replication AR ophthalmoplegia(81)  
  RRM2B dNTP metabolism  AD/AR ophthalmoplegia(74)  
  SLC25A4 dNTP metabolism  AD ophthalmoplegia(82)  
AD: autosomal dominant, AR: autosomal recessive, MMA: methylmalonic acid, PEO: 




2.4   MITOCHONDRIAL DNA POLYMERASE GAMMA (pol γ) 
Polymerase gamma (pol γ) is the only DNA polymerase within the mitochondrion of 
animal cells that replicates and repairs the mitochondrial genome (84).  The enzyme is 
a heterotrimer (Figure 5) composed of one catalytic subunit (polγA) of 139kDa, encoded 
by POLG on chromosome 15q25, and a dimer of two accessory subunits (polγ B) of 
53kDa, encoded by POLG2 on chromosome 17. While the catalytic subunit is 
responsible for DNA synthesis and proof-reading the accessory subunit promotes DNA 
binding and processivity (85).  
Figure 5: The structure of the pol γ enzyme 
 
 
The pol γ enzyme is comprised of catalytic subunit, polγA (blue) and two accessory 
subunits (green and pink). Protein data bank ID:3iKM (85).  
 
The catalytic core of pol γ comprises: A) a mitochondrial leader sequence (MLS); B) an 




polymerase active site; and D) the spacer (linker region) which separates the 
exonuclease and polymerase domains (Figure 6). 
Figure 6: The linearized structure of the catalytic pol γ subunit 
    
Linear schematic diagram. The catalytic subunit comprises MLS, exonuclease, palm, 
thumb, fingers and linker domains.  
 
The polymerase domain consists of three sub-domains: A) the palm sub-domain 
(residues 816-910 and 1096-1239), a positively charged domain stabilizing the 
negatively charged DNA backbone and containing the polymerase catalytic site and two 
Mg2+ ions, which are vital for formation of the phosphodiester bond between the 3’OH 
end and the phosphate group of the incoming nucleotide (dNTP); B) The fingers sub-
domain (residues 911-1095), which is involved in binding the incoming dNTP substrate; 
C) the thumb sub-domain (residues 441-475 and 785-815), which forms the major 
surface of the DNA binding channel. The linker domain (residues 476-785) comprises 
two sub-domains: the accessory interacting sub-domain, which forms a major 
hydrophobic contact with the proximal accessory subunits and the intrinsic processivity 
domain which forms a region for the upstream DNA binding. The exonuclease domain 









2.5      POLG DISEASE 
2.5.1   General overview  
The first pathogenic variant in the POLG gene was identified in families with autosomal 
dominant Progressive External Ophthalmoplegia (adPEO) (OMIN 157640) in 2001 
(87). Since then, an increasing number of overlapping phenotypes with wide variation 
in the age of disease onset have been linked to pathogenic variants in the POLG gene.   
The true prevalence of POLG disease is unknown, however, it has been estimated to be 
about 10-25 % of all adult patients with mitochondrial disorders (10, 83). The most 
common reported variants causing human diseases are c.2243G>C (p.Trp748Ser), 
c.1399G>A (p.Ala467Thr) and c.2542G>A (p.Gly848Ser) (88-91). The carrier 
frequency of p.Trp748Ser is estimated to be 1:125 in Finland (92), while for 
p.Ala467Thr it is estimated at 0.6% in Belgium and 1% in Norway (93, 94). Thus, the 
combined frequency of p.Trp748Ser and p.Ala467Thr maybe is as high as 1:50 in the 
Norwegian population (88). Variants in POLG have also been described in other non-
European ethic groups (95).  
The majority of POLG-related phenotypes are inherited as autosomal recessive traits. 
Pathogenic variants within the POLG gene can be homozygous or compound 
heterozygous. These variants can either decrease the processivity of polymerase gamma, 
its affinity for native DNA or the speed at which it incorporates nucleotides. Autosomal 
recessive phenotypes usually present early in life, however, onset late in adulthood has 
also been reported (96).  
Almost all the variants which are associated with adPEO are in the polymerase domain 
(97). Variants in this domain usually interfere with the translocation and binding affinity 
to incoming nucleotide, which may result in increased mtDNA replication errors and 
decreased catalytic function. AdPEO patients usually present in adulthood (90). One 
patient with the p.Tyr955His mutation and early onset disease with bilateral 
sensorineural hearing loss, cataract, myopathy, and liver failure has however been 




As would be expected from the disruption of mtDNA caused by POLG mutation, almost 
all organ systems can be affected (table 3), but tissues with high energy demand and 
organs such as the brain, muscle and liver are particularly susceptible (84, 87, 89, 91, 
92, 99-104).  
Table 3: Major organ systems which are affected and related clinical manifestations in 
individuals with POLG disease 
 
Organ system Clinical features 
Central nervous system Seizures / status epilepticus 
  Ataxia 
  Hypotonia* 
  Stroke-like episodes 
  Migraine-like headache 
  Encephalopathy 
  Parkinsonism 
Gastro-intestinal  Failure to thrive  
  Liver dysfunction/ failure  
  Gastro-intestinal dysfunction  
Musculoskeletal  Ptosis  
  PEO 
  Myopathy 
  Exercise intolerance 
Psychiatric  Psychosis 
  Depression 
  Hallucination  
Peripheral neuropathy Axonal sensory neuropathy 
Vision  Cortical blindness  
  Cataract 
  Retinopathy 
Hearing  Sensorineural hearing loss  
Endocrine Primary ovarian failure  
  Primary testicular failure  
  Diabetes  
Cardiac  Cardiomyopathy  
 






2.5.2   Major clinical phenotypes  
A. MyoCerebroHepatopathy Spectrum (MCHS):  
MCHS is a severe and fatal phenotype that usually presents very early in the neonatal 
period with a triad of myopathy/hypotonia, encephalopathy/developmental delay and 
liver failure. Other findings include failure to thrive, renal tubular acidosis, cataract, and 
hearing loss. Diagnostic criteria for MCHS include: absence of  hepatic 
histopathological features of classical Alpers-Hunttenlocher syndrome and at least two 
of the following: neuropathy, seizures, elevated blood or cerebrospinal fluid (CSF) 
lactate, dicarboxylic aciduria, renal tubular dysfunction with aminoaciduria, glycosuria 
or bicarbonaturia, hearing loss, abnormal MRI with either cerebral volume loss, delayed 
myelination or white matter disease, and either isolated deficiency of complex IV or a 
combined defect of two or more OXPHOS complexes in skeletal muscle or liver biopsy 
(84, 90, 100, 102, 105). 
B. Alpers-Huttenlocher syndrome (AHS):   
Alpers-Huttenlocher syndrome (AHS) (OMIM # 203700) is the most frequently 
reported phenotype in infancy and early childhood (106), although disease onset can 
occur at any time during childhood or early adulthood (107, 108). AHS was first 
recognised by Bernard Alpers in 1931, long before its genetic basis was identified, and 
diagnosis was based on typical neuropathological findings. Subsequently, when the 
association with liver involvement was described by Petter Huttenlocher, it was called 
Alpers-Huttenlocher syndrome (109, 110). It was not until the 1980s that the link to 
mitochondrial dysfunction was made (111) and the link to polymerase gamma was made 
first in 1999 (99). Pathogenic POLG variants causing AHS were first reported in 2004 
(112).  
AHS is characterized clinically by a triad of progressive encephalopathy with 
psychomotor regression, refractory epilepsy and liver disease (103).  A prodromal phase 
with mild developmental delay, hypotonia and failure to thrive may occur and an 
infectious illness may precede the disease onset (113). Focal seizures, commonly 




epileptiform discharges predominantly seen over the occipital regions, at least initially 
(89, 114). The clinical features of occipital lobe involvement such as visual 
hallucination, vomiting and headache are less clearly manifested in young children than 
older children and adults. The majority of the patients develop myoclonic seizures and 
episodes of epilepsia partialis continua (EPC) and/or generalized status epilepticus (SE). 
Patients with AHS may also present with refractory SE from which they might never 
recover (84, 89, 115).  
Patients with AHS may develop episodes of acute exacerbation that previously have 
been called stroke-like episodes (SLEs). These episodes are characterized by acute or 
subacute neurological dysfunction and are often associated with EPC. The aetiology of 
these episodes is neuronal dysfunction leading to damage, not vascular occlusion (116). 
In the older age group, prodromal symptoms such as migraine-like headaches, visual 
disturbance, and mental changes may occur. Clinically, such episodes are less often 
reported in children compared with adults, but radiological evidence of cortical lesions 
is common in both (117). 
Hepatic involvement is a major feature of early onset POLG disease and may progress 
rapidly to end stage liver failure. Affected children with normal, mild, and transient 
abnormalities of liver function are, however, well recognized (91, 102). Liver failure 
can occur spontaneously or be triggered by sodium valproate (88, 118). Recovery after 
transient liver failure and after the discontinuation of sodium valproate has been reported 
(114). Nevertheless, sodium valproate clearly accelerates the development of liver 
failure in patients with pathogenic variants in the POLG gene and its use is absolutely 
contraindicated.  
C. Myoclonic epilepsy myopathy sensory ataxia (MEMSA): 
MEMSA (also referred to as mitochondrial spinocerebellar ataxia with epilepsy - 
MSCAE) includes a spectrum of manifestations: mainly epilepsy, ataxia and myopathy. 
Seizures, including SE, can be the first manifestation. Ataxia, which is often present at 




Myopathy and ophthalmoplegia develop later, if the patient survives the consequences 
of the epilepsy (89, 94, 100).   
Seizure semiology is similar to AHS with focal seizures, commonly evolving into 
bilateral convulsive seizures, being the most common seizure type. However, myoclonic 
seizures, epilepsia partialis continua and generalized SE are frequently reported (119). 
Occipital lobe features, including visual hallucinations, scotomata, hemianopia and 
amaurosis, are common (88, 94). Episodes of encephalopathy, previously called SLEs, 
are more frequently reported than with AHS (117). Vomiting and migraine-like 
headache with aura occur and may precede the acute episodes. Hepatic dysfunction 
including liver failure is also a feature of MEMSA and may occur spontaneously or can 
be triggered by usage of sodium valproate as in AHS (88, 120).  
D: Ataxia Neuropathy Spectrum (ANS): 
Ataxia Neuropathy Spectrum is characterized by ataxia, neuropathy and encephalopathy 
that usually presents in adulthood and which can be associated with prolonged survival. 
The neuropathy may be sensory, motor or mixed and is usually severe enough to 
contribute to ataxia. The encephalopathy is  slowly progressive (100). Individuals with 
ANS may also develop cognitive decline and psychiatric symptoms including 
depression.  Ophthalmoplegia is more often a late feature and predominant myopathy is 
rare (91, 92, 101). Liver dysfunction may also occur, ranging from mildly elevated liver 
enzymes to liver failure. Seizures have also been reported, however, these are not a 
major feature of ANS (88, 90, 100). Other terms for this phenotype include 
mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy 
dysarthria and ophthalmoplegia (SANDO).  
E: Progressive external ophthalmoplegia (PEO):  
Pathogenic variants in the POLG gene can cause both autosomal dominant and 
autosomal recessive PEO. Affected individuals suffer from progressive weakness of the 
extraocular muscles resulting in unilateral or bilateral symmetrical ptosis and loss of eye 




such as ataxia, peripheral neuropathy and generalized myopathy occur more frequently 
in the recessive form (arPEO) than in the dominant form (adPEO), and usually develop 
later during the disease course (87, 90, 100, 121-123). Other features which can be seen 
in individuals with adPEO may include sensorineural hearing loss (91), parkinsonism 
(101, 124), premature menopause (101, 121), male infertility (125), cataract (101) and 
depression (101). 
In addition to the above described major clinical syndromes, variants in POLG have 
been associated with a spectrum of overlapping clinical phenotypes. The terminology 
used to describe these phenotypes has evolved haphazardly, becoming more 
complicated and difficult to use in an everyday clinical setting. A summary of the 
reported POLG related phenotypes with major clinical features and age of onset is 

















Table 4: Summary of the major syndromes associated with pathogenic variants in  
POLG gene  reported in literature (126), reprinted with permission.    
Phenotype Nomenclatures(reference) Major clinical features  Age of onset 
Myocerebrohepatopathy (MCHS)(90, 105, 106)  
 
 
Myopathy, hypotonia, developmental delay, 





Alpers-Huttenlocher Syndrome (AHS)(103, 105, 112) 
 
 
Encephalopathy, psychomotor regression, 





Alpers syndrome (84, 127) Synonym of AHS  As in AHS 
Alpers-Huttenlocher like(128)  Synonym of AHS  As in AHS 
Infantile hepatocerebral syndrome(105)  
 





Infantile mitochondrial DNA depletion 
syndrome(129)  
 






Leigh like(129)  
 
Psychomotor retardation, hypotonia,  




hyperintensities on T2 weighted images in 
basal ganglia, brain stem, thalamus  
Mitochondrial Neuro-Gastro-Intestinal  




Severe gastrointestinal dysmotility, 









Myoclonus, Epilepsy, Myopathy and  
Sensory Ataxia (MEMSA) (84) 
 
Epilepsy, myopathy, ataxia, liver 





Spinocerebellar ataxia with Epilepsy (SCAE)(84, 100) 
 
Now incorporated under MEMSA umbrella 
 
As in MEMSA 
 
Mitochondrial Spinocerebellar ataxia with  
Epilepsy (MSCAE)(115) 
Now incorporated under MEMSA umbrella  
 
As in MEMSA 
 
Ataxia Neuropathy Spectrum (ANS)(84, 100) 
 
Ataxia, neuropathy, psychiatric symptoms,  
epilepsy and ophthalmoplegia 
Adolescent and 
adult 
Mitochondrial recessive ataxia syndrome Now incorporated under ANS umbrella As in ANS 
(MIRAS)(92)        
Sensory ataxia neuropathy dysarthria Now incorporated under ANS umbrella As in ANS 
and ophthalmoplegia (SANDO)(84) 
   
MELAS like phenotype(131) 
 




Recessive Charcot-Marie Tooth like(132)  
 
 
Axonal polyneuropathy, muscle weakness, 





Parkinsonism(101, 124)  
 




Autosomal recessive progressive  
external ophthalmoplegia (arPEO)(87, 100) 
Ptosis, ophthalmoparesis, may be 
associated with ataxia and myopathy 
Adult, elderly 
 
Autosomal dominant  progressive external 
ophthalmoplegia (adPEO)(87, 100) 
 






Chronic progressive external  Synonym of adPEO  Adult-elderly 





2.5.3 Diagnosis   
A. Clinical awareness: 
As with most mitochondrial disorders, the diagnosis of POLG disease is challenging 
owing to the extreme clinical heterogeneity of presentation, particularly in the paediatric 
population. There is no single clinical feature that is diagnostic for POLG disease, 
however, certain groups of symptoms and signs may provide a clue: for instance, disease 
onset soon after birth with hypotonia, failure to thrive and liver failure, but no seizures, 
would suggest MCHS. Presentation with acute-onset status epilepticus preceded by 
headache and visual disturbances and MRI changes suggestive of ischaemia in an 
adolescent or adults may raise the suspicion of MEMSA. EEG, biochemical and neuro-
imaging findings, as described below, may also provide clues to the diagnosis. However 
none of those are diagnostic for POLG disease. 
A detailed family and medical history and a thorough physical examination of central 
and peripheral nervous systems, as well as evaluation of the possible involvement of 
other organ systems and assessment of vision, hearing, growth and psycho-motor 
development are still essential initial steps to achieve the diagnosis.  
The diagnosis of POLG disease should not only be considered in individuals presenting 
with one of the classic POLG phenotypes, since a large proportion of  patients with 
POLG disease do not present with a discrete clinical syndrome (83). POLG disease 
should also be considered in patients with therapy resistant epilepsy, unexplained 
encephalopathy or ataxia.  The difficulties associated with making the diagnosis of 








B. Biochemical analysis: 
There are no specific blood or urine biomarkers for POLG disease. Peripheral blood 
lactate is a marker for mitochondrial disease generally, however, normal blood lactate 
does not exclude the diagnosis of POLG disease as elevation can be mild, transient or 
even absent. Further, inappropriate collection may result in a falsely pathologic high 
value. Pyruvate/lactate ratio can be used to indicate OXPHOS impairment (127, 133). 
Both lactate and pyruvate can be measured in the CSF, however, lack of specificity 
limits their diagnostic value since elevated CSF lactate can occur in other conditions 
such as seizures of other cause, and CNS inflammation  and infection (134). 
Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are 
both potential biomarkers for mitochondrial disorders (135, 136).  FGF21 has been 
reported to be elevated mainly in individuals with manifestations in skeletal muscle and 
appears rarely elevated in POLG disease. Values ranging from 25pg/ml to > 4000 pg/ml 
have however been reported in patients with AHS and in a single patient with ANS with 
terminal SE (135).  FGF21 and GDF15 can be used as additional biomarkers in the initial 
diagnostic process and might have prognostic implications as FGF21 and GDF15 values 
appear to correlate with disease severity (135, 136). Nevertheless, negative results 
should not exclude the diagnosis. Owing to the observation of normal values in many 
patients with POLG disease, FGF21 and GDF15 are not considered useful markers to 
establish the diagnosis. Other findings such as low CSF folate, the presence of CSF 
oligoclonal bands, and raised CSF NF-L have also been reported, however, none is 
specific for POLG disease (137-139).  
 
General blood and urine investigations including full blood count, glucose, creatine 
kinase (CK), liver transaminases, liver and renal function tests and urine analysis should 
be performed to evaluate the systemic involvement of the disease. Metabolic screening 
with measurement of plasma amino acid and acylcarnitine profiles and urinary organic 
acids are helpful to exclude other metabolic/mitochondrial disorders that may mimic 





C. Histopathology and respiratory chain enzymology: 
Classical mitochondrial muscle pathology findings such as ragged-red and cytochrome 
oxidase (COX) negative fibres can be seen in patients with POLG disease, however, 
these can be absent in patients with early onset disease (140). Adolescent patients may 
have less than 1% of COX-negative fibres, emphasizing that the major manifestations 
are in the CNS.  Further, infants with normal muscle biopsy may have severe 
pathological liver changes (141). The characteristic hepatic histopathological changes 
of AHS which are required for the diagnosis are namely the presence of at least two of 
the following: microvesicular steatosis, bile ductular proliferation, hepatocyte dropout, 
bridging fibrosis or cirrhosis, collapse of liver cell plates, parenchymal lobular 
architecture, regenerative nodules and oncocytic changes in scattered hepatocytes not 
affected by steatosis (106). 
In addition to morphological examination, mitochondrial RC analysis in muscle may 
provide a diagnostic clue. RC enzyme analysis may show isolated enzyme deficiency or 
combined deficiencies of multiple enzymes, especially in patients with primary muscle 
involvement, but the results may also be normal. Pathogenic variants in the POLG gene 
demonstrate tissue specific predilections and thus RC enzyme deficiencies may only be 
identified in clinically affected tissues such as liver or brain (83, 84).  
 
D. Neurophysiological findings:  
EEG findings may give a clue to the diagnosis of POLG disease in individuals with 
seizures. Ictal and inter-ictal occipital epileptic activity are highly suggestive of POLG 
disease. Focal epileptic discharges over the temporal and frontal regions can however 
also be observed and multifocal or generalized epileptic activity may occur during 
seizure evolution and SE (89, 119).  Other EEG changes such as rhythmic high 
amplitude delta (RHADs) and focal slowing are frequently observed (114, 119).  
Nerve conduction studies will confirm the presence of peripheral neuropathy 
particularly in juvenile and adult onset disease (88). POLG disease is mostly associated 
with axonal changes and a predominantly sensory and some motor component 





Brain MRI is the modality of choice and the recommended sequences are T2 fluid-
attenuated inversion recovery (FLAIR-T2) and diffusion weighted imaging (DWI).  The 
most prevalent abnormalities are T2 / T2-FLAIR hyperintensities in the cerebral cortex, 
also known as cortical focal lesions (CFLs), which occur in patients with epilepsy and 
mainly affect the occipital regions although involvement of other regions such as 
parietal, temporal and frontal lobes may also occur (119). These changes may evolve 
over days or weeks and subsequent partial or complete regression may occur (88, 117, 
119). Neuroimaging studies may, however, be normal early in the disease course and 
should not exclude the possibility of POLG disease. 
 Other neuroimaging abnormalities include lesions in the thalamus, olivary nucleus, and 
cerebellar white matter which may remain stable throughout the disease course. 
Generalized brain atrophy develops later during the disease course and is progressive, 
reflecting the clinical progression of the disease (117, 119, 120).  
MRS of CFLs often shows a prominent lactate peak due to impaired aerobic respiration 
and decreased N-acetyl aspartate concentration which reflects neuronal loss (117). Ictal 
Cerebral FDG-PET imaging in the acute phase shows increased glucose uptake over 
these lesions (120).   
F. Molecular genetic:  
When the diagnosis of POLG disease is suspected clinically, direct sequencing of the 
POLG gene is the most appropriate first-line investigation. The inclusion of POLG in 
next generation sequencing (NGS) gene panels for epilepsy, ataxia and mitochondrial 
disorders should facilitate early diagnosis. In some regions, screening for the common 
founder mutations; p.Ala467Thr, p.Trp784Ser, and p.Gly848Ser may still be 
appropriate (87, 144). The finding of pathological variants in POLG, biallelic in 
recessive disease and heterozygous in dominant disease, establishes the diagnosis.     
New variants in the POLG gene continue to be identified. Determining the pathogenicity 
of such variants as ‘pathogenic’, ‘likely pathogenic’ or of ‘uncertain significance’ can 




Polymerase Gamma Mutation Database (https://tools.niehs.nih.gov/polg/), and the 
POLG Pathogenicity Prediction Server (http://polg.bmb.msu.edu/) (145). Further, the 
identification of new variants either requires extensive laboratory research to prove its 
pathogenicity or verification by finding more families.   Ideally, all pathological variants 
should be reported in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), however many 
laboratories are either slow or forget to submit variants. These challenges highlight the 
difficulties in establishing the definite genetic diagnosis in some individuals with 
POLG-related phenotypes and new variants in POLG gene.   
2.5.4 Management  
Currently, there are no cures for POLG disease.  Clinical management is mainly 
symptomatic and based on conventional approaches to treat the clinical manifestations 
and associated complications. As in other rare diseases with high mortality, randomized 
controlled clinical trials are still lacking and may be challenging to perform as designing 
a trial is likely to be extremely difficult in the view of clinical heterogeneity, 
unpredictable clinical course, and spontaneous resolution of features such as SLE or 
cerebral ischaemia.  Understanding the natural history of the disease may help to 
establish a clinical baseline which can be used in comparison in single-arm clinical trials 
for potential therapies. Unfortunately, however, earlier descriptions of the natural 
history of POLG disease were often based on case reports or cohorts with limited 
numbers of patients, making large cohorts such as ours even more valuable.  
A. Management of epilepsy:  
The presence of epilepsy is associated with increased mortality and morbidity in patients 
with POLG disease (88, 146). Early recognition and immediate, aggressive seizure 
treatment are crucial to improve patient survival. The majority develop therapy resistant 
seizures (88, 119) and this is particularly true for infants and children. Treatment with a 
single AED is usually not effective and high dose, multiple AED treatment is often 




management in POLG disease and several AEDs have been used in various dosages and 
combinations.  
No specific single or combined AEDs have been shown to be particularly effective in 
treating the seizures in POLG disease. AEDs known to be effective in treatment of focal 
seizures such as oxcarbazepine, carbamazepine, lacosamide and perampanel are 
appropriate, as focal and focal evolving to bilateral convulsive seizures are among the 
most common types.  Lamotrigine, topiramate and levetiracetam have also been used, 
alone and in combination with a benzodiazepine such as clobazam or clonazepam. 
Lamotrigine can worsen mycolonic seizures and should be used with caution (89, 115, 
146).   
Sodium valproate is absolutely contraindicated due to the risk of acute and progressive 
hepatic necrosis (88).  Transient liver failure with recovery after discontinuation of 
sodium valproate has been reported (114). If the clinical presentation raises the suspicion 
of POLG disease, sequencing of the POLG gene should be considered before prescribing 
sodium valproate, particularly in those with status epilepticus of unknown aetiology.  
(118).  
Management of SE is challenging; benzodiazepines, phenytoin and levetiracetam can 
be used as first line treatment, however, failure to control the seizures is common.  In a 
case of refractory SE, anaesthetic agents as propofol or a barbiturate (pentothal) should 
be instituted promptly. Propofol should be used with caution due to the risk of propofol 
infusion syndrome particularly in the paediatric population. Other agents as ketamine 
(147), magnesium infusion (148) and corticosteroids (114) have been reported to be 
effective in terminating SE in single cases, however, data available regarding the 
effectiveness are currently insufficient. Epilepsia partialis continua is generally resistant 
to pharmacotherapy.  
Other non-pharmacological alternatives including ketogenic diet and vagus nerve 
stimulation have been used (149), but currently, there are insufficient data confirming 
the benefit of either of these entities in patients with POLG disease. Transcranial direct 




however a recent publication showed it was not effective (151). Palliative functional 
hemispherectomy can be an option when the short-term benefits outweigh the risk of 
surgery (152).  
There is no clear evidence showing any significant clinical effect of nutritional 
supplements such as co-enzyme Q10, folic acid, carnitine, L-arginine, EPI-734 or other 
vitamins, although these are widely used. Further studies need to be performed to 
investigate the effectiveness of these agents. (153, 154).  
B: Gastrointestinal and nutritional:  
Feeding difficulties and failure to thrive, mainly in the very young, and vomiting/gastric 
dysmotility regardless of the age of onset are common gastro-intestinal features of 
POLG disease (84, 127, 155). Evaluation by a gastroenterologist and dietician and the 
use of enteral nutrition via gastric tube/gastrostomy should be considered early during 
the disease course, particularly in young individuals.   
C. Liver dysfunction:  
Liver dysfunction is a common feature of POLG disease regardless of the age of onset 
and can range from acute and progressive liver failure to mild/transient elevation of liver 
enzymes. Liver dysfunction can also occur spontaneously or as a consequence of sodium 
valproate exposure. Spontaneous resolution of liver failure after exposure to sodium 
valproate has been reported (156). Close monitoring of the liver function by measuring 
liver enzymes (AST, ALT, GGT) and other liver function parameters such as ammonia, 
albumin, bilirubin, prothrombin time, is highly recommended and should be performed 
routinely at least every 3 to 4 months, especially in infants, children and adolescents.  
Liver transplantation remains an option and it has been performed in more 40 patients 
with POLG disease (83, 157-159). However, there is some controversy around the use 
of liver transplantation, particularly in early onset disease, due to the aggressive nature 
of the disease and early death due to neurological decline occurring within one year of 




better than with early onset disease (88, 90, 160). Thorough evaluation of the ethical 
aspects and an individualized risk-benefit analysis in all cases, regardless of age, are 
needed before proceeding to transplantation (160-162).  
D. Movement disorders:  
Parkinsonism is a feature of late-onset disease (101) and usually occurs together with 
PEO and peripheral neuropathy. However, early onset parkinsonism was reported in two 
sisters who also had neuropathy, but not PEO (124). Treatment with L-Dopa (163) 
appeared to be effective in some cases. Benzodiazepines may reduce the severity of 
other non-epileptic movement disorders including myoclonus and tremor. In individuals 
with dystonia, local injections with botulinum toxin and oral/intrathecal baclofen can be 
useful. 
E. Ophthalmological manifestations:   
Individuals with POLG disease may develop cortical blindness, nystagmus, ptosis and 
ophthalmoplegia and should be referred for ophthalmological evaluation. Surgery for 
ptosis may be considered and may provide some symptomatic relief, although post-











3. AIMS OF THE THESIS  
3.1 GENERAL AIMS 
The overarching aim of the work in this thesis was to bridge the translational gap 
between research and clinical practice in order to facilitate faster and more accurate 
diagnosis, and impact the management of patients with POLG disease.  
3.2 SPECIFIC AIMS  
- To study the clinical spectrum and the natural course of POLG disease in a large 
cohort of patients to provide a detailed description of the disease’s phenotypic-
spectrum and a reliable clinical classification which can be used both in paediatric 
and adult populations. 
-  To identify robust diagnostic and prognostic biomarkers which may help to 






















4.1 STUDY DESIGN AND POPULATION 
In these multinational, retrospective studies 159 patients were recruited from 13 centres 
in seven European countries: Norway (Haukeland University Hospital, Oslo University 
Hospital, St. Olav’s Hospital and University Hospital of Northern Norway); United 
Kingdom (Great Ormond Street Hospital, London and Welcome Trust Centre for 
Mitochondrial  Research, Institute of Neuroscience, Newcastle University); Sweden 
(Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm 
and The Queen Silvia Children's Hospital, University of Gothenburg), Denmark 
(Department of Clinical Genetics, Copenhagen University Hospital); Finland 
(Children's Hospital, Helsinki University Hospital and Clinic for Children and 
Adolescents, Oulu University Hospital); Netherlands (Department of Genetics and Cell 
Biology, Maastricht  University, Maastricht) and Spain (Sant Joan de Déu Children´s 
Hospital, Barcelona) (figure 7).   
Figure 7: The European countries participating in this study highlighted in green.  
 




The Norwegian patients were recruited from the National Norwegian POLG Registry, 
(www.polgregister.no). Collaboration was established with all Norwegian university 
hospitals and a local investigator responsible for data collection was allocated in each 
centre. By June 2018, 76 patients had been enrolled in the registry. Distribution of 
patients according to the health-regions (Central, Northern, Southern and Eastern and 
Western Norway) is provided in figure 8.       
Figure 8: Distribution of patients with POLG disease in Norway according to the four 
health regions; Central: red, Northern: blue, Southern and Eastern: yellow, Western: 
green. 
                                     
 
 
The majority of patients included in this study were Northern European (n=150), but 
there were three from Iraq, two from Cyprus and one each from Croatia, Pakistan, Spain 





In view of the rarity of MCHS, and to provide a better understanding of this particular 
phenotype, a systematic literature review (using search terms “POLG”, “mitochondria”, 
“Alpers”, “infantile hepatocerebral syndromes”, “mtDNA depletion”, 
“myocerebrohepatopathy syndrome” performed in PubMed, June 2016) was used to 
identify previously published cases. Cases fulfilling the criteria for MCHS (106) and 
confirmed biallelic pathogenic POLG variants were included. These additional MCHS 
cases were just included in paper I. 
A large database of patients with POLG disease was assembled and analysed in step-
wise fashion. Details regarding number of patients, recruiting-centres and period of data 
entry for each part of the study are provided in table 5. In paper I, only data from 
individuals with disease onset before 12 years of age was included, while in papers II, 
III and IV available data from all the individuals, regardless of the age of onset were 
included. Patients (n=4) recruited from the Centre for Mitochondrial Research, 
















Table 5: Recruiting-centres, number of patients and period of data entry. 
Study part 
 




 Data-entry period 
 
Paper I     May 2015- July 2016 
 Norway:  8  
 Haukeland University Hospital, Bergen   
 University Hospital of Northern Norway, Tromsø   
 United Kingdom:  19  
 Great Ormond Street Hospital, London   
 Total 27  
Paper II     May 2015- December 2017 
 Norway:  76  
 Haukeland University Hospital, Bergen   
 University Hospital of Northern Norway, Tromsø   
 St. Olav’s Hospital, Trondheim   
 Oslo University Hospital, Oslo   
 United Kingdom:  19  
 Great Ormond Street Hospital, London    
 Sweden:  44  
 Karolinska University Hospital, Stockholm   
 The Queen Silvia Children's Hospital, Gothenburg   
 Denmark: 5  
 Copenhagen University Hospital, Copenhagen   
 Finland:  8  
 Helsinki University Hospital, Helsinki   
 Oulu University Hospital, Oulu   
 Netherlands: 2  
 Maastricht University, Maastricht    
 Spain:  1  
 Sant Joan de Déu Children´s Hospital, Barcelona   
 Total 155  
   Paper III     May 2015-  June 2017 
 Norway:  50  
 Haukeland University Hospital, Bergen   
 University Hospital of Northern Norway, Tromsø   
 St. Olav’s Hospital, Trondheim   
 Oslo University Hospital, Oslo   
 United Kingdom:  9  
 Great Ormond Street Hospital, London   
 Sweden: 19  
 Karolinska University Hospital Stockholm   
 The Queen Silvia Children's Hospital, Gothenburg    
 Finland:   5  
 Helsinki University Hospital, Helsinki   
 Oulu University Hospital, Oulu   
 Total  83  
   Paper IV     May2015- December2016 
 Norway: 45  
 Haukeland University Hospital, Bergen   
 University Hospital of Northern Norway, Tromsø    
 St. Olav’s Hospital, Trondheim   
 Oslo University Hospital, Oslo   
 United Kingdom:  16  
 Great Ormond Street Hospital, London    
 Centre for Mitochondrial Research, Newcastle    




4.2 INCLUSION CRITERIA  
Individuals diagnosed and followed at the participating centres were considered eligible 
if they had recessive disease and confirmed biallelic pathogenic POLG variants or 
dominant disease and a heterozygous, confirmed pathogenic variant.  Individuals with 
novel variants considered pathological and clinical features consistent with POLG 
disease were also included.   
4.3 DATA COLLECTION 
Data were recorded on an electronic-case report form (eCRF) completed by the 
responsible investigator(s) at each centre and reviewed by the study-monitor (O.H).    
The eCRF was developed and tested in a pilot study of 10 patients conducted at 
Haukeland University Hospital, Bergen, Norway. The electronic version of the eCRF 
(WebCRF) was developed by the Unit for Applied Clinical Research Faculty of      
Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 
(https://webcrf3.medisin.ntnu.no/). 
4.4 STUDY DATA 
Detailed clinical, biochemical, muscle biopsy, neurophysiological, neuroimaging and 
genetics data were obtained (Appendix 1). The date of disease onset was defined by the 
date of symptom(s) necessitating the patient’s first medical evaluation. The age of onset 
of each individual symptom was also identified. End of follow up was defined as the 
date of the patients’ last visit to the treating centre or death. Preterm birth was defined 
as birth before a gestational age of 37 completed weeks. Microcephaly was defined as 
head circumference more than two standard deviations below the mean for age and sex.   
Anaemia was defined as an abnormally low haemoglobin value according to age and 
sex adjusted values (164). Renal tubulopathy was defined by the presence of at least 
three of the following: tubular acidosis with generalised aminoaciduria, tubular 
proteinuria, glycosuria, increase in urinary N-acetyl-beta-D-glucosaminidase 
(NAG)/creatinine ratio, or Fanconi syndrome. Liver involvement was defined by the 




aspartate aminotransferase (ASAT), gamma-glutamyltransferase (GGT), bilirubin or 
ammonia, low serum albumin, or pathological histological findings on liver biopsy.  
CSF protein and/or albumin values at disease onset and during the disease course were 
obtained. Since the reference normal range for CSF protein may be age dependent, we 
looked at the values according to age (165-167). Since albumin is produced exclusively 
in the liver, all albumin detected in CSF originates, by definition, from blood. The level 
of CSF albumin provides, therefore, a parameter with which to evaluate the permeability 
of the blood-CSF barrier. The ratio of CSF to serum albumin (Q-alb) corrects for the 
individual’s albumin level and provides a reflection of the diffusion gradient of albumin 
(165, 168-170). This ratio was calculated as CSF albumin (milligram (mg)/L)/serum 
albumin (g/L). The reference range for Q-alb is also age dependent. The cut-offs used 
in this study were reported in supplementary file 2, paper III (171). 
Hearing impairment was defined as abnormal auditory evoked response test. Therapy 
resistant epilepsy was defined using the International League Against Epilepsy (ILAE) 
definition (172).  
POLG variant(s) for each case were identified either by targeted mutation analysis for 
specific common mutations (c.1399G>A, p.Ala467Thr and c.2243G>C, p.Trp748Ser, 
and Gly848Ser) or by sequence analysis of all coding regions of POLG gene. 
4.5 STATISTICAL ANALYSIS 
Data were analysed using SPSS (Statistical Package of Social Sciences). A two sided P 
value less than 0.05 was considered to be statistically significant. Categories were 
compared using Fisher’s Exact tests when appropriate.  
In paper II, Correspondence Analysis (CA) was performed to examine the relationship 
between two variables graphically in a multidimensional space. These variables were: 
A) groups of patients who were classified according to the age of disease onset (early 
onset, juvenile and adult, and late onset disease), and B) the age of onset of each 




each age group. Further, mosaic plots were performed to study the differences between 
these groups.  
For survival analysis, the end-point was time to death which was defined as the time in 
months from the date of onset to the date of death. Univariate survival analysis was 
performed using log-rank test (Kaplan Meier) to compare differences in survival time 
between categories. Adobe illustrator CS6 and BioRender (biorender.com) were used to 
create and edit the figures. 
4.6 ETHICAL STATEMENT 
The ethical approval for the study was obtained from the Regional Committee for 
Medical and Health Research Ethics, Western Norway (REK 2014/1783-4). Each 
participating country obtained approval from their local ethical committee. The study 
was registered as an audit at Great Ormond Street Hospital, London, UK (Registration 
Number 1675).  Anonymised data regarding Newcastle patients was provided courtesy 
of the MRC Mitochondrial Disease Patient Cohort (Ethics ref:13/NE/0326). All 
procedures followed were in accordance with the ethical standards of the responsible 
committee both in Norway and in the other collaborating countries and with the Helsinki 














5.1 Paper I: The clinical spectrum and natural history of early-onset diseases due to 
DNA polymerase gamma mutations 
The primary aim was to study the natural history of paediatric onset POLG disease in a 
sufficiently large cohort of patients to provide a better and more detailed description of 
the clinical spectrum in this age group. Clinical, biochemical, neuro-imaging and genetic 
data of 27 individuals with recessive disease and biallelic variants in POLG in whom 
initial symptomatology manifested prior to the age of 12 years were obtained.  
The median age of disease onset was 11 months (range 2 weeks to 7 years). Extensive 
phenotypic characterisation was performed. Six patients fulfilled diagnostic criteria for 
MCHS, 19 for AHS, and one had a MNGIE-like phenotype. One patient was 
unclassified owing to insufficient data. The majority presented with global 
developmental delay (n=24/24, 100%), hypotonia (n=22/23, 96%), liver dysfunction 
(n=23/25, 92%) and failure to thrive (n=24/27, 89 %). Seizures were also common 
(n=19/26, 73%) and were present in 89% (n=17/19) at disease onset. Focal and focal 
evolving to bilateral convulsive seizures with epileptiform activities predominantly seen 
over the occipital regions were the most commonly reported seizure types. Notably, 
none of the patients with the MCHS phenotype had seizures.  
Lactate was elevated in blood in 60% of those in whom this was measured (n=12/20) 
and in CSF in 40% of those in whom CSF studies were performed (n=2/5). Abnormal 
respiratory chain enzyme activities were observed in 9 of 14 cases in whom muscle 
biopsy was performed. Interestingly, most AHS patients had normal respiratory chain 
enzyme activities or only an isolated deficiency of a single enzyme complex, while those 
with MCHS had multiple respiratory chain complex deficiencies.  
The most common MRI findings were cortical focal lesions manifesting as T2/FLAIR 
hyperintensities involving cortical and subcortical areas, predominantly affecting the 




All cases had two biallelic pathogenic POLG variants identified either by targeted 
mutation analysis for specific common variants as p.Ala467Thr and p.Trp748Ser or by 
sequence analysis of all coding regions of POLG. Two patients (no. 23 and no. 26, 
supplementary file 1, paper I) with classical AHS phenotype and novel POLG gene 
variants (p.Lys498Thr, p.Gly621Asp) were included. All POLG gene variants reported 
in this part of the study and associated phenotypes are illustrated in Figure 2 paper I.  
Survival analysis showed that median age at death was 15.8 months (range 1.0 to 184.6 
months), whereas median time from disease onset to death was 4.9 months (range 0.5 to 
181.2 months). The main causes of death were liver failure, followed by sepsis and status 
epilepticus. Median survival time of patients with disease onset ≤12 months was 3.6 
months ( range 0.5-181) compared to 10 months (range 1.4-82) for those with disease 
onset >12 months. Survival analysis by phenotype showed that the median survival time 
for patients with MCHS was 5 months (range 0.6-22) and 4 months (range 0.5- 181) for 
AHS. 
This study showed the multi-systemic nature and natural history of early onset POLG 
disease and highlighted the existence of a disease group without seizures - i.e. those with 
the MCHS phenotype. The common founder variants p.Ala467Thr and p.Trp748Ser 
were present in only one of our cases with MCHS and a review of the literature showed 
only one additional case with this variant, confirming the need to sequence the whole 
POLG gene rather than perform targeted variant analysis. Further, we extended the 
phenotypic spectrum of childhood POLG disease to include a phenotype with prominent 
gastro-intestinal symptoms mimicking mitochondrial neurogastro-intestinal 
encephalomyopathy (MNGIE), in addition to the AHS and MCHS phenotypes. Based 
on the results of this study, we observed that early onset POLG disease could be 







5.2 Paper II: Simplifying the clinical classification of polymerase gamma (POLG) 
disease based on age of onset: studies using a cohort of 155 cases  
The aim of this study was to provide a simple clinical classification that would facilitate 
early clinical recognition of patients with POLG disease. To do this, we systematically 
reviewed detailed longitudinal data from 155 patients both at disease onset and later 
during the disease course. The cohort included patients with disease onset from birth to 
late adulthood, providing us with a unique opportunity to study the clinical spectrum of 
the disease during the whole life span.   
The age of onset of each individual symptom was identified. Median age at disease onset 
for the whole study cohort was 10 years (range: birth – 71 years). Fifty-four percent 
(n=83/155) had onset prior to the age of 12 years, 34% (n=53/155) had onset between 
12 and 40 years of age, and 12% (n=19/155) had onset after the age of 40 years. Disease 
debut was apparently spontaneous in 113/155 (73%), followed an infectious illness in 
32/155 (21%) and not clearly reported in 10/155 (6%) of the patients.  
Neurological (90%, n=139/155), ophthalmological (74%, n=112/151) and 
gastrointestinal (63%, n=92/146) symptoms were the predominant clinical features. 
Epilepsy was reported in 69% (n=107/155), with focal and focal evolving to bilateral 
tonic-clonic seizures being the most common seizure types (92%, n=94/102). Ataxia 
(63%, n=87/138), peripheral neuropathy (53%, n= 65/123), and hypotonia (50%, 
n=68/135) were frequently reported. Nystagmus (38%, n=55/146), PEO (38%, 
n=56/146) and ptosis (34%, n=51/149) were the most commonly reported 
ophthalmological features. Liver involvement was identified in 64% (n=96/151) of the 
patients. More than half of the study cohort had feeding difficulties (52%, n=75/145), 
regardless of the age of onset. A detailed description of the clinical features, laboratory, 
muscle-biopsy, neuro-physiology and neuro-imaging findings is provided in table 2 and 
supplementary tables 1 and 2, paper II. 
Our data confirmed that POLG disease comprises a continuum of clinical features rather 
than a set of separate clinical identities (see figure 1 paper II). Nevertheless, by grouping 




differences (table 3 paper II). Liver involvement (87%), seizures (84%) and feeding 
difficulties (84%) were the major features in those with onset prior to the age of 12 years, 
while ataxia (90%), peripheral neuropathy (84%) and seizures (71%) occurred most in 
those with onset between the age 12 and 40 years, and ptosis (95%), progressive external 
ophthalmoplegia (89) and ataxia (58%) in those with onset after the age of 40 years. 
Early onset was associated with a worse prognosis. Cluster analysis showed there was 
obvious clustering of the symptoms around the three different age groups and further 
mosaic plots confirmed statistically significant differences in the phenotypes seen in the 
above mentioned groups (supplementary figure 2, paper II).  
A total of 41 different POLG variants were identified in the 155 individuals described 
in this study. Ninety patients had compound heterozygous variants, 59 had homozygous 
variants and six patients had a heterozygous variant associated with autosomal dominant 
disease, mainly adPEO. The majority of patients with early onset disease (70%) had 
compound heterozygous pathogenic POLG variants (regardless of the variant types), 
while 62% of those with juvenile/adult onset had homozygous pathogenic variants. 
POLG gene variants reported in this part of the study are summarized in supplementary 
figure 3, paper II.  
The main cause of death for the whole cohort was liver failure, followed by 
infection/sepsis, multi-organ failure and SE, and was unknown in 13% of the 
individuals. The presence of epilepsy was associated with significantly worse survival, 
and the median survival time from seizure onset to death was 37 months (range < 1 - 
487). Survival after the onset of seizures in those with early onset disease was 
significantly worse than those who developed seizures as part of juvenile/adult onset 
disease. Analysis also showed that patients with pathogenic compound heterozygous 
POLG variants had significantly worse survival than those with pathogenic homozygous 
variants. Further, individuals with liver involvement showed a significantly worse 





5.3 Paper III: Elevated cerebrospinal fluid protein in POLG-related epilepsy: 
Diagnostic and prognostic implications 
Since epilepsy is common in individuals with POLG disease and the disruption of blood 
brain barrier (BBB) has been described in many neurological disorders that include 
epilepsy (Table 1, paper III), the aim of this study was to assess whether BBB 
dysfunction occurs in POLG disease and what clinical implications it has for patients. 
Our study cohort contained 83 patients with details of CSF protein/albumin. We used 
the presence of a raised CSF/serum ratio of albumin (Q-alb) to evaluate the integrity of 
BBB. 
This study demonstrated that elevated CSF protein was a common feature of POLG 
disease; raised CSF protein was observed in 70% of patients in whom data were 
available (n=58 /83) and was, moreover, associated with the most severe phenotypes.  
The finding of a significantly elevated Q-albumin ratio indicated a clear dysfunction of 
the BBB. We found that the majority of those with epilepsy (n=50/66, 76%) had raised 
CSF protein and interestingly, this preceded seizure debut in 75% (n=15/20). This study 
showed that elevated CSF protein can be used as a biomarker both to facilitate early 
diagnosis and to identify those at high risk of developing epilepsy. 
 
5.4 Paper IV:  The presence of anaemia negatively influences survival in patients 
with POLG disease 
Mitochondria are known to play an important role in iron metabolism and thus 
haematopoietic cell homeostasis. Little attention has been given to the haematological 
manifestations in patients with mitochondrial disease particularly those with POLG 
disease. Recent studies performed in the POLG mutator mouse model demonstrated that 
variants in POLG can also drive haematopoietic abnormalities including anaemia (173-
177). This study aimed to determine the frequency of and outcomes associated with 




Approximately two third of the patients (n= 41/61, 67%) enrolled in this study 
developed anaemia at some stage and, importantly, almost one in four (n=14/61, 23 %) 
had anaemia already at presentation. This was particularly true for patients with early 
onset POLG disease (AHS and MCHS phenotypes) who had a high frequency of 
anaemia (n= 18/ 25, 72%) with 35% (n=8/23) having anaemia at presentation. Details 
regarding the number of individuals with anaemia stratified according to age group is 
provided in table 2, paper IV. 
Survival analysis (Figure 1, paper IV) revealed that the presence of anaemia was 
associated with a significantly worse survival. This part of the study demonstrated for 
the first time that anaemia is indeed a feature of POLG disease in humans and is 
associated with significantly worse survival and can be used as a predictor for poor 





6.  DISCUSSION  
The aim of this study was to provide a thorough description of the natural history and 
the phenotypic spectrum of POLG disease, and to elaborate a robust, but simple clinical 
classification to guide clinicians and help predict the prognosis.  
The cornerstone of clinical diagnosis is a relevant clinical, phenotypic classification that 
is useful in everyday clinical practice. This, however, is challenging in mitochondrial 
disorders due to poor phenotype:genotype correlation, namely that defects in a single 
gene, such as POLG, may give rise to multiple clinical phenotypes. This means that even 
affected individuals in the same family, sharing the same pathogenic variant may present 
with different phenotypes, and that unrelated individuals with different pathogenic 
variants may share the same phenotypes (83, 84, 100).  Understanding the natural history 
of a disease is essential to address these challenges since this will provide information 
about the evolution of clinical features and the related morbidity and mortality.  
Classification of POLG disease has developed haphazardly and resulted in a plethora of 
eponymous and syndromic categories (Table 3). This has made clinical recognition 
challenging and can, potentially, have resulted in delayed or even missed diagnosis. 
Since data describing the natural history of POLG disease in a sufficiently large cohort 
of patients were lacking, we established the largest known cohort of individuals with 
POLG disease by recruiting individuals from the National Norwegian POLG Registry 
and from our international collaborating centres. Clinical, laboratory, neuro-
physiological and neuroimaging findings were reviewed both at the disease onset and 
later during the disease course.  This enabled us to describe in detail the clinical spectrum 
and the natural history of the disease in a sufficiently large number of patients. Further, 
data from our thorough national history studies allowed us to classify POLG disease 
more simply than the earlier attempts. We believe that such a classification is easier to 
implement in clinical practice and will facilitate early clinical recognition. We were also 





6.1 NATURAL HISTORY AND THE PHENOTYPIC SPECTRUM OF POLG 
DISEASE 
6.1.1 Paper I: The clinical spectrum and natural history of early-onset diseases due 
to DNA polymerase gamma mutations 
In this study, we focused on early onset disease. We looked at paediatric patients with 
disease onset prior to the age of 12 years and generated a comprehensive clinical and 
laboratory description of the features present at onset and later during the disease course. 
In addition, we reviewed the neurophysiological, histopathological and neuro-imaging 
findings and performed a phenotype-genotype correlation study.   
We found that the majority of patients with early onset POLG disease had relatively 
diffuse clinical manifestations such as hypotonia, failure to thrive, developmental delay 
and seizures. These findings highlight the challenges associated with making the 
diagnosis of POLG disease in the paediatric population. These non-specific clinical 
manifestations overlap with the manifestations of many other disorders including 
mitochondrial and non-mitochondrial disorders. For example, pathogenic variants in 
nuclear genes such as PARS2, NARS2, FARS2, SURF1, PDHA1 and ADCK3 (83, 178-
180), or those affecting mtDNA stability (summarized in table 2), may all mimic POLG 
phenotypes clinically.  Defects  in mtDNA  such as the m.3243A>G mutation causing 
MELAS (181), may also mimic the early and juvenile forms of POLG disease. The 
differential diagnosis of non-mitochondrial disorders resembling POLG disease is also 
wide and includes febrile infection related epilepsy syndrome (FIRES) (182), 
autoimmune encephalitis/Rasmussen encephalitis with EPC (183), and other inborn 
errors of metabolism with recurrent liver failure such as that caused by pathogenic 
mutations in NBAS gene (184) or neonatal hypoglycaemia and non-ketotic 
hyperglycinaemia (185).  
Survival analysis showed that early onset disease is associated with high mortality 
(n=22/26, 85%) and the median survival time from disease onset to death was 5 months, 




The majority of individuals in this paediatric cohort were classified as AHS or MCHS. 
We also found one patient who fulfilled the criteria for MNGIE and were, therefore, 
able to expand the POLG phenotypic spectrum in this age category. One patient 
remained unclassified owing to insufficient data. Our findings were also in broad 
agreement with the earlier understanding that MCHS and AHS can be considered as two 
separate entities; we found clear differences in the age of onset and the survival between 
these two patient groups. Nevertheless, since few of the patients had liver biopsy 
performed (liver biopsy was only performed in 3 cases), it was not possible to 
differentiate these two phenotypes as previously suggested (106). This probably reflects 
everyday clinical practice where liver biopsy is rarely performed in early onset POLG 
disease due to the associated risks and is contraindicated in the case of severe liver 
dysfunction. We did find one important feature that differentiated these two phenotypes: 
none of the individuals with MCHS phenotype had epilepsy (Table 3, paper I). This was 
true not only in our cohort, but also when we collected all previously published cases of 
MCHS (Table 2, paper I). Based on these findings, we concluded that the previously 
described clinical and histopathological criteria used to differentiate between AHS and 
MCHS phenotypes were not applicable and we suggested a simplified classification of 
early onset disease into those with or without epilepsy. 
Patients with MCHS who underwent biochemical measurements also showed the most 
severe respiratory chain defects (supplementary file 2, paper I). We hypothesised that 
these patients were the more severely affected and, possibly because of this, died before 
the onset of seizures. Discordance in the outcome observed in one sibling pair (cases 15 
and 16) provides further evidence for this hypothesis. Case 15 with an AHS phenotype 
died at 9 months with intractable seizures whereas his sister (case 16) with a MCHS 
phenotype died at 5 months and never developed seizures.  
Our data also led us to believe that the MCHS phenotype (i.e. early onset disease without 
epilepsy) may be under diagnosed due to the presence of non-specific clinical features 
and absence of epilepsy, the most common factor that triggers the clinical suspicion of 




possibility of POLG disease arising in the absence of epilepsy, will improve the clinical 
ascertainment of patients in this age group.  
When we looked at the genotypes in the group of MCHS patients, we found that the 
common variants (c.2243G>C, p.Trp748Ser and c.1399G>A, p.Ala467Thr) occurred 
only once (patient 16, paper I) in our MCHS group. Moreover, we found only one other 
previously published MCHS case with these variants (186). These findings suggest that 
screening only for common POLG mutations in children younger than 12 years with 
unexplained encephalopathy, or multi-system neurological disorders, as previously 
suggested (91, 144), will be unsuccessful.  
 
6.1.2 Paper II: Simplifying the clinical classification of polymerase gamma (POLG) 
disease based on age of onset: studies using a cohort of 155 cases 
In the second study, we wished to extend our work to include all age groups and at the 
same time include sufficient numbers of patients to enable us to make robust statements 
concerning the natural history and the clinical spectrum of POLG disease. To do this we 
used all the available data  from the National Norwegian POLG Registry, data from our 
ongoing collaboration in the Mitochondrial Clinical Research Network (MCRN) 
(www.mcrnet.org ) and data from patients in our first study that were recruited from  
Great Ormond Street Hospital, London, UK. We were able to recruit 155 patients and 
thus establish the largest known cohort of patients with POLG disease. This large 
multicentre/international cohort gave us a unique opportunity to study the natural history 
of POLG disease through all ages, to increase the power of statistical analysis, and 
eliminate any potential geographical bias.  
Since our cohort contained longitudinal data, including clinical, laboratory and neuro-
imaging data at disease onset and during the disease course, we could show that POLG 
disease comprised a continuum of clinical features (Figure 1, paper II). These data 
showed clearly that features such as ataxia, seizures, liver dysfunction and peripheral 
neuropathy could arise at any point from infancy to older age. Indeed, it was clear that 




arise at different times and overlap with one another. This suggested to us that POLG 
disease was a continuum rather than a set of separate clinical identities (Table 1). 
While we felt that the finding of a continuum of features mitigated against multiple 
different clinical entities, we observed that when we looked at the median age of onset 
of the major features, there was a tendency for these to cluster according to age (Figure 
1 paper II). We, therefore, re-analysed the data using three age groups (Table 3, paper 
II). Based on these findings, we showed that the clinical spectrum of POLG disease 
could be described by stratifying the patients simply according to the age of disease 
onset. 1.) An early onset disease (onset prior to the age of 12 years) - liver involvement, 
feeding difficulties, seizures, hypotonia, and muscle weakness were the most common/ 
easily recognizable clinical features and this group had the worst prognosis. 2.) A 
juvenile/adult onset (onset from 12 - 40 years of age) - characterized by peripheral 
neuropathy, ataxia, seizures and SLE. Patients in this group carried a better prognosis 
than the early onset group. 3.) A late onset disease (onset after the age of 40 years) - 
characterized by ptosis and PEO. Other features such as peripheral neuropathy ataxia 
and muscle weakness may also occur. This group had the best prognosis.  
To confirm our findings, we performed cluster analysis which showed a clear clustering 
of the symptoms around the age groups mentioned above (supplementary figure 1, paper 
II). Further, mosaic plots confirmed statistically significant differences in the 
phenotypes observed in these groups (supplementary figure 2, paper II).  
Based on our age groups, clear clinical patterns could be identified and these dictated 
which investigations were appropriate and useful to reach the diagnosis. We used these 
data to generate a diagnostic algorithm (Figure 3, paper II) to show how recognition of 
the key clinical features could be used to direct the diagnostic investigations in the 
different age groups.  
We believe that our simple clinical classification of POLG disease into these three 
groups - early onset, juvenile to adult, and late onset disease - will facilitate early clinical 





Age of disease onset was clearly correlated to the survival time (Table 3, paper II), the 
earlier the onset, the worse the prognosis. Moreover, survival analysis showed that the 
presence of epilepsy was significantly associated with worse prognosis (Figure 2, paper 
II). Further, individuals who developed liver involvement showed significantly worse 
survival than those without liver involvement (supplementary figure 4, paper II). 
Regarding the impact of the genotype on survival, we found that individuals with 
compound heterozygous POLG variants had a worse prognosis compared to those with 
homozygous variants, regardless of variant type (Figure 2, paper II). We believe that 
data concerning the features mentioned above, age of onset, seizure, liver involvement 
and/or the identification of specific genotype (i.e. compound heterozygous), can inform 
everyday clinical practice and help us guide patients/families regarding the prognosis of 
POLG disease. 
6.2 NOVEL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS  
Biomarkers (biological markers) are defined in general as: ‘A characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention’ (187). 
In mitochondrial disorders, biomarkers have been used to facilitate early diagnosis, 
selecting patients who should undergo more invasive diagnostic procedures and 
providing information about disease outcome (188).  
Our studies in POLG disease showed that laboratory biomarkers commonly used in the 
initial diagnostic work up such as blood and CSF lactate, the presence of ragged-
red/COX-negative fibres and abnormal respiratory chain activities in the skeletal muscle 
had low diagnostic sensitivity, being present in less than 50% of the individuals. This is 
particularly true in the paediatric population.  
In the third and fourth studies of this thesis, we examined two novel biomarkers and 






6.2.1 Paper III: Elevated cerebrospinal fluid protein in POLG-related epilepsy: 
Diagnostic and prognostic implications 
This study investigated whether POLG disease is associated with disruption of BBB 
and, if so, what the diagnostic and/or prognostic implications were for the affected 
individuals.  
Clinical, laboratory and genetic data of 83 individuals were available for this study. The 
laboratory data included CSF protein and/or albumin values. The study revealed that 
more than two thirds of those studied (70%) had raised CSF protein and/or albumin.  
When we used the ratio of CSF/serum albumin (Q-alb) to evaluate the integrity of the 
BBB, we found markedly raised levels (median value of 21.5 x 10–3) in the 18 
individuals in whom these were measured. Indeed, the Q-alb ratios were higher in 
individuals with POLG disease than in other disorders in which BBB dysfunction also 
occurs (Table 1, paper III) suggesting a profound disruption of BBB integrity. Further, 
the availability of longitudinal clinical and laboratory data allowed us to follow disease 
progression and enabled us to show that there was a progressive deterioration of BBB 
integrity as both the proportion of those with abnormal raised CSF protein and the actual 
CSF protein value increased with time.    
Raised CSF protein was also associated with worse prognosis (regardless of the age of 
disease onset). Median survival time for those with raised CSF protein was markedly 
decreased (13 months) compared to those with normal CSF protein (32 months). 
Further, our analysis showed that raised CSF protein mainly occurred in patients with 
epilepsy (76%) and interestingly, its presence preceded the onset of the seizures (n= 
15/20).  This finding has important clinical implications and suggests that raised CSF 
protein can be used as a biomarker to identify those at risk of developing epilepsy.   
We also found that the proportion of individuals with elevated protein/albumin was 
higher than the proportion of patients having abnormalities of other commonly used 
diagnostic biomarkers (Table 3, paper III). This suggests that elevated CSF protein has 
a higher diagnostic sensitivity than tests such as blood lactate and may be useful as a 




The role of mitochondria in the integrity of the BBB has been investigated; in vitro 
inhibition of complex I with rotenone, impairing ATP production using carbonyl 
cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP) or inhibiting complex V with 
oligomycin can result in disruption of  BBB  integrity and increase its permeability 
(189). Further, inhibition of mitochondrial respiratory chain enzyme activity in mice by 
epidural administration of rotenone impaired BBB integrity and was associated with 
marked increase in BBB permeability (189).  Disruption of the BBB permits circulating 
large molecular proteins such as albumin to enter into the brain microenvironment. 
Uptake of these molecules by neurons or astrocytes (190) is followed by down-
regulation of extracellular potassium buffering capacity (191), which in turn  facilitates 
N-methyl-D-aspartate receptor mediated neuronal hyperexcitability (192, 193), and the 
release of proinflammatory cytokines (190, 194, 195). All of these mechanisms may 
lead either to seizures or lower the threshold for seizure initiation (192, 196, 197). Based 
on our findings, and work by others (189, 190, 192, 197), we hypothesized that 
mitochondrial dysfunction induced by pathogenic variants in POLG gene leads to 
disruption of the BBB tight junctions and leakage of proteins such as albumin. Uptake 
of albumin by astrocytes and neurons initiates a cascade of events that contribute to 
seizure development (Figure 1, paper III) and subsequent worsening of the BBB 
dysfunction. 
6.2.2 Paper IV:  The presence of anaemia negatively influences survival in patients 
with POLG disease 
This study was inspired by previous work showing that polγ-deficient mice manifested 
haematopoietic abnormalities including anaemia (173-177).  The aim of the study was 
to investigate whether anaemia was a feature of POLG disease in humans.  
Haematological abnormalities associated with POLG disease have not previously been 
reported. We assumed, therefore, it was likely that the serious nature of the neurological 
and hepatic manifestations may have obscured the significance of the haematological 
abnormalities. In the absence of human data, we analysed the frequency of anaemia in 




We showed that anaemia is indeed a feature of POLG disease in humans with 
approximately two third of the individuals studied developing anaemia during the course 
of their disease, and almost one in four having anaemia at disease onset. The frequency 
of anaemia was even higher (72%) in individuals with early onset disease, and 35% of 
these had anaemia at the disease onset. This may reflect the severity of the disease in 
this age group. Further, survival analysis showed that the presence of anaemia was 
significantly associated with worse survival (Figure 1, paper IV). This finding has an 
important clinical implication as the presence of anaemia can be used as a negative 
prognostic biomarker.  
When thinking about how the anaemia arose in POLG disease, we hypothesised that it 
was due to deceased RBC production based on the following observations: A) None of 
the individuals enrolled in this study had any clinical or laboratory evidence of 
haemolysis or blood loss at the time that anaemia was recorded. B) Those who 
developed terminal multi-organ failure already had anaemia registered at an earlier time 
point. Individuals who developed anaemia due to bleeding as a part of multi-organ 
failure were not included. C) The presence of anaemia at disease onset argues strongly 
against an “anaemia of chronic disease” or it being due to the influence of therapy e.g. 
AEDs. D) Only 35 % (5/14) of those with anaemia at disease onset had evidence of  liver 
impairment (three with only mild elevation of ASAT or ALAT, and two with early onset 
disease without epilepsy with clear evidence of liver failure), suggesting liver 
dysfunction was most probably not the cause of the anaemia. Lastly, our hypothesis is 
supported by the animal studies showing that POLG mutation is associated with 
anaemia, haematopoietic progenitor dysfunction and erythroid dysplasia (173-177). 
We were unable to classify the type of anaemia in the majority of individuals enrolled 
in this study owing to insufficient data, however available data suggested iron deficiency 
was the major cause.  
The question of whether we are missing a potential therapeutic opportunity by not 
treating anaemia remains unresolved. A study using matched quantitative genomic and 




dose-dependent decrease of mitochondrial proteins and oxidative capacity which was 
fully reversed when iron was reintroduced (198). A subsequent study performed by the 
same group  showed that the transcriptional changes were accompanied by alterations 
to histone acetylation and methylation levels that were largely reversible by 
reintroduction of iron (199). Prospective studies are needed to investigate whether 
treating anaemia and optimizing iron level will improve the survival and decrease the 
morbidity in patients with POLG disease.  
6.3 LIMITATIONS OF THE PRESENT STUDIES: 
As shown by our studies, one strength of retrospective studies is the ability to 
accumulate data from a large number of patients. Another strength is that patients are 
unselected. A major weakness of such studies is that there is often a great deal of missed 
data, which may have the effect of reducing the size and power of the study. This 
disadvantage would be compounded if the missing data were not distributed randomly.  
Our study population was diverse enough to include all the known POLG clinical 
phenotypes. This provided us with a unique opportunity to produce robust and 
statistically significant conclusions. Nevertheless, missing data did influence some of 
our sub-analyses such as in paper III where CSF/serum ratio of albumin could only be 
measured in 18 of the 83 individuals enrolled in the study. Another example of this was 
seen in paper IV where we were unable to identify the cause of anaemia in the majority 
of the individuals, again due to missing data.  
The clinical forms used to acquire data were completed by many investigators based in 
different centres. This too might have generated discrepancies in the data collected. We 
were, however, able to minimize this potential disadvantage by having regular study-
meetings in which we first went through the study form in detail, and then discussed the 
quality of the collected data and the results of the studies as the project progressed. 
Further, all the forms were quality checked by O.H.   
There is also the question of ethnicity. Individuals included in this study were mainly of 
Northern European descent. While this may limit the impact of this study to other ethnic 




cohort is the largest known group of patients with POLG disease and included all the 
known phenotypes previously associated with POLG disease and more than 40 different 
POLG variants. Moreover, there is no evidence in the literature of marked ethnic 
differences in phenotypic expression of POLG disease. We can therefore suppose that 
our findings are relevant to patients with POLG disease, regardless of the ethnic 
background.      
 
7. CONCLUSION 
The studies performed as part of the PhD thesis allow us to make some important 
observations. We found that the clinical data were best explained by POLG disease 
being a continuum rather than a collection of separate phenotypes. Nevertheless, we did 
see that age played an important role: we found that by classifying patients simply 
according to age of onset it was possible to elucidate three groups; early onset, juvenile 
/adult onset and late onset disease with clear phenotypic and prognostic differences. We 
hope that our classification and thorough description of the natural history will help 
facilitate early clinical recognition of the disease, help physicians to direct the laboratory 
investigations and be useful in predicting the outcome of patients with POLG disease 
(Figure 3, paper II). 
Highlighting the existence of early onset POLG disease without seizures will hopefully 
improve diagnosis of this subgroup of patients with rapidly fatal disease. Since affected 
individuals rarely have the so-called ‘common’ POLG variants, we state the need for 
full screening of the POLG gene. This applies equally to patients in the neonatal period 
and during childhood with unexplained encephalopathy and multi-system disorders with 
or without epilepsy.  
 
Our studies also enabled us to identify commonly available prognostic biomarkers such 
as CSF protein and haemoglobin concentration.  Further, we showed that age of disease 




epilepsy and/or liver impairment, and those who were compound heterozygous for 
POLG variants had a significantly worse prognosis.   
In light of the difficulties associated with performing randomized controlled clinical 
trials in rare disorders such as POLG disease, we believe our natural history data, based 
on a large number of individuals, will help physicians to establish a clinical baseline for 
comparison in single-arm clinical trials for potential novel therapies in the future.   
 
8. FUTURE PROSPECTS 
The available data from this large cohort of individuals with POLG disease is still not 
completely analysed. The impact of gender is an important question we need to address: 
based on clinical observations, females with POLG disease appear more severely 
affected during puberty and pregnancy. Further, we need to analyse our data regarding 
the efficacy of AED(s) to reduce seizure frequency and severity so that we may provide 
an evidence based guideline for treatment of epilepsy in patients with POLG disease.  
Previous studies have shown conflicting results regarding the effect of nutritional 
supplements such as co-enzyme Q10, carnitine and vitamin cocktails, which are widely 
used in the treatment of mitochondrial disorders. Using our cohort, we hope to address 
the question of whether these supplements have any positive effect to stop the disease 
progression, reduce seizure frequency or improve the survival in patients with POLG 
disease.     
Another important area that has not been sufficiently studied is the quality of life in 
patients with POLG disease. We are currently conducting a study using standardized 
questionnaires to evaluate the quality of life and mental health status of individuals with 
POLG disease.   
Our ongoing collaboration with the members of the MCRN (Mitochondrial Clinical 
Research Network) and with the Mitochondrial Research Group, Genetics and Genomic 
Medicine Program at UCL Great Ormond Street Institute of Child Health, will enable 
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                              POLG related disorders 
                                         CASE REPORT FORM (CRF) 
                                                   
Site ID: _ _             Patient ID: _ _ _ _       Date of registration:   _ _ /_ _ / _ _ _ _ 
                                                                    Date of re-entry:        _ _ /_ _ /_ _ _ _ 
Mito-Server ID: _ _ _                                 Bio-bank ID: _ _ _            
Registration performed by:    _ _ _ _           Registration controlled by:  _ _ _ _ 
 
                                     Inclusion Criteria  
Genetically verified pathologic POLG mutations        □ Yes        □ No  
 
                                       Demographics  
 
 Date of birth:_ _ / _ _ /_ _ _ _   (dd/ mm/yyyy) 
 Gender: □  male            □ female                                                            □ unknown 
 Ethnic group:  
□ Caucasian □ Black □Asian □ other, specify ______                         □unknown  
 Resident country: ________________,    □ unknown 
 Resident county ( for Norwegian patients only)  : ________________,    □ unknown 
 Hospital name ( for Norwegian patients only) : ________________,        □ unknown 
 
 
                                        Family History  
 Parental consanguinity:       □ yes        □ no                                             □ Unknown  
 
If yes specify:  __________________________ 
 
 Presence of a known mitochondrial disease phenotype in relative: 
 □ yes                               □ no                                                                 □ unknown 
If yes specify:____________________________ 
 
 Phenotype: specify,________________________, □ unknown 
 Gender:  □  male            □ female          □ unknown 
 Origin of relatedness: □ paternal         □ maternal    □ both      □ unknown 
 Degree of relatedness:  □ 1st □ 2nd  □ other ______                  □ unknown 
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                         Disease onset and last follow up Dates 
 
 Onset date :      _ _ /_ _ / _ _ _ _  ( dd/mm/yyyy) 
 
 Last follow up: _ _ / _ _ / _ _ _ _  ( dd/ mm/yyyy) 
 
 
                                               Growth  
 
 At disease onset : 
 Weight:            ____ (kg)  □ unknown 
 Height:             ____ (cm) □ unknown 
 Head cf. :         ____ (cm) □ unknown 
 
 At last follow up:  
 
 Weight:            ____ (kg)  □ unknown 
 Height:             ____ (cm) □ unknown 
 Head cf. :         ____ (cm) □ unknown 
 
          Diagnostic Testing For Suspected Mitochondrial Disease 
 
 Muscle biopsy:      □ performed, date _ _/_ _ /_ _ _ _ (dd/ mm/yyyy)      □ not done 
 Liver biopsy:          □ performed, date _ _/_ _ /_ _ _ _ ( dd/mm/yyyy)     □ not done 
 Fibroblast:              □ performed, date_ _/ _ _ /_ _ _ _ ( dd/mm/yyyy)      □ not done 
 Genetic investigation:□ performed, date _ _/_ _ /_ _ _ _ ( dd/mm/yyyy)  □ not done 
 Other test:               □ performed, date _ _ /_ _ /_ _ _ _ ( dd/mm/yyyy)     □ not done 
 
                                      Genetic Findings 
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                                     Perinatal History  
 
 Mother age at birth: _ _  (years )                                                                 □  unknown  
 Gestational age (weeks) : □ < 35   □ 35-37  □ 38-41   □  > 41            □ unknown  
 Intra-uterine growth retardation: □ yes  □ no                                          □ unknown  
 Placenta pathology:                     □ yes   □ no                                        □ unknown 
 Birth weight: ____ kg    □ AGA      □ SGA         □  LGA                   □ unknown  
 Head cf. at birth: ___cm □ normal   □ microcephaly □ macrocephaly □ unknown 
 APGAR 1-5-10 : ____-____-____ □ unknown 
 Pathological signs at birth: □ yes  □ no                                                 □ unknown  
If yes: 
 Need for resuscitation:       □ yes  □ no                                     □ unknown  
 Hypotonia:                          □ yes   □ no                                      □ unknown 
 Hypertonia:                         □ yes   □ no                                      □ unknown 
 Seizures:                              □ yes   □ no                                     □ unknown 
 Respiratory complications: □ yes   □ no                                      □ unknown 
 Cardiac complications:        □ yes   □ no                                    □ unknown 
 Dysmorphic features:          □ yes   □ no                                    □ unknown 
 Hyperlactatemia:                 □ yes   □ no                                    □ unknown 
 pH value at birth :  ______                                                            □ unknown  
 Base access value at birth : ____                                                   □ unknown 
 Hyperglycaemia:                  □ yes   □ no                                   □ unknown 
 Hypoglycaemia:                   □ yes   □ no                                  □ unknown 
 Feeding difficulties :            □ yes   □ no                                  □ unknown 
 Vomiting :                            □ yes   □ no                                  □ unknown 
 Anaemia:                              □ yes   □ no                                  □ unknown 
 Other :                                  □ yes   □ no                                  □ unknown 
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                                      Disease Debut  
 
 Spontaneous:                   □ yes   □ no                                               □ unknown 
 Post infectious:                □ yes   □ no                                               □ unknown 
 Post epileptic:                  □ yes   □ no                                               □ unknown  
 Post puberty:                    □ yes   □ no     □ not applicable      □ unknown 
 Post Menarche:                □ yes   □ no        □ not applicable          □ unknown 
 Other:                               □ yes   □ no                                               □ unknown 
If yes, specify: ___________ 
 
                 Registered Mitochondrial disease diagnosis  
 
 ICD code : __ _ _ _                                                                               □ unknown 
 Date of definitive diagnosis:       _ _ /_ _/_ _                                       □ unknown 
 Alpers-Hunttenlocher syndrome:                      □ yes   □ no              □ unknown 
 Myocerebrohepatopathy spectrum:                   □ yes   □ no              □ unknown 
 Myoclonic epilepsy myopathy sensory ataxia: □ yes   □ no               □ unknown 
 Ataxia Neuropathy spectrum:                           □ yes   □ no               □ unknown 
 Progressive external ophthalmoplegia( PEO):  □ yes   □ no               □ unknown 
 Autosomal recessive PEO:                    □ yes   □ no               □ unknown 
 Autosomal dominant PEO:                    □ yes   □ no               □ unknown 
 Unclassified:                                          □ yes   □ no               □ unknown 
 
 Other:                                                                 □ yes   □ no               □ unknown 
If yes specify: ______________ 
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                                   Clinical Features 
 
 Neurological disorders: 
If yes specify: 
 Seizures:     □ yes                 □ no                                                □ unknown   
                             If yes, specify: 
 
 Generalized: □ yes   □ no                                                  □ unknown   
If yes,          Debut: □ at onset  □ later, Date_ _ / _ _/_ _ □   unknown 
                    Present at last follow up: □ yes □ no            □ unknown  
 
Infantile spasms: □ yes   □ no                                          □ unknown   
If yes,          Debut: □ at onset   □ later, Date_ _/  _ _/_ _□   unknown 
                    Present at last follow up: □ yes □ no            □ unknown 
Myoclonus epilepsy: □ yes   □ no                                     □ unknown   
If yes,          Debut: □ at onset   □ later, Date_ _/ _ _/_ _ □   unknown 
                    Present at last follow up: □ yes □ no            □ unknown 
Status epilepticus: □ yes   □ no                                        □ unknown   
If yes,          Debut: □ at onset  □ later, Date _ _/ _ _/_ _□   unknown 
                    Present at last follow up: □ yes □ no            □ unknown 
 Focal: □ yes   □ no                                                            □ unknown   
If yes, Specify: _________ 
                    Debut: □ at onset   □ later, Date _ _/ _ _/_ _□   unknown 
                    Present at last follow up: □ yes □ no            □ unknown    
 
Epilepsia partialis continue: □ yes   □ no                         □ unknown   
If yes,          Debut: □ at onset   □ later, Date _ _ /_ _/_ _□   unknown 
                    Present at last follow up: □ yes □ no            □ unknown    
 
 Other:  □ yes   □ no                                                           □ unknown 
If yes, Specify: ____________           
                   Debut: □ at onset   □ later, Date _ _ /_ _/_ _ □   unknown 
                    Present at last follow up: □ yes □ no            □ unknown 
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 Therapy resistant: □ yes   □ no                                        □ unknown 
If yes, specify; ____________         
                  Debut: □ at onset   □ later, Date _ _/_ _/_ _  □ unknown 
                  Present at last follow up: □ yes □ no             □ unknown 
 
 
 Cerebrovascular: □ yes   □ no                                                     □ unknown   
If yes, specify: 
 Stroke: □ yes   □ no                                                         □ unknown   
If yes, Specify: _________ 
                 Debut: □ at onset   □ later, Date_ _/ _ _/_ _   □ unknown 
                                                     Present at last follow up: □ yes □ no             □ unknown    
 Stroke like episodes: □ yes   □ no                                    □  unknown                                            
If yes, Specify: _________ 
               Debut: □ at onset   □ later, Date _ _/_ _/_ _     □ unknown 
               Present at last follow up: □ yes □ no                □ unknown    
 Migraine: □ yes   □ no                                                     □ unknown   
If yes, Specify: _________ 
                                                 Debut: □ at onset   □ later, Date _ _/_ _/_ _       □ unknown 
                                                 Present at last follow up: □ yes □ no                  □ unknown    
 Motor: □ yes   □ no                                                                     □ unknown   
If yes, specify:  
 Limb weakness: □ yes   □ no                                          □ unknown   
If yes, specify character: _________ 
                                                 Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
                                                 Present at last follow up: □ yes □ no                 □ unknown    
 Muscle atrophy: □ yes   □ no                                         □ unknown   
If yes, specify character: _________ 
           Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
           Present at last follow up: □ yes □ no                  □ unknown    
 Hypotonia: □ yes   □ no                                                 □ unknown   
If yes, specify character: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
                                                Present at last follow up: □ yes □ no                  □ unknown    
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 Hypertonia: □ yes   □ no                                                □ unknown   
If yes, specify character: _________ 
             Debut: □ at onset   □ later, Date _ _/_ _/_ _     □ unknown 
             Present at last follow up: □ yes □ no                □ unknown    
 
 
 Dystonia: □ yes   □ no                                                    □ unknown   
      If yes, Specify: _________ 
                                                Debut: □ at onset   □ later, Date_ _/ _ _/_ _       □ unknown 
            Present at last follow up: □ yes □ no                  □ unknown    
 Ataxia: □ yes   □ no                                                        □ unknown   
If yes, Specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
            Present at last follow up: □ yes □ no                 □ unknown    
 Spasticity : □ yes   □ no                                                  □ unknown   
If yes, Specify: _________ 
                                                 Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
                                                 Present at last follow up: □ yes □ no                 □ unknown    
 Weakness  □ yes   □ no                                                   □ unknown   
If yes, specify: _________ 
                                                Debut: □ at onset   □ later, Date _ _/_ _/_ _       □ unknown 
            Present at last follow up: □ yes □ no                  □ unknown    
 Bradykinesia: □ yes   □ no                                             □ unknown   
If yes, specify: ________ 
                                                 Debut: □ at onset   □ later, Date _ _/_ _/_ _     □ unknown 
             Present at last follow up: □ yes □ no                □ unknown    
 Chorea/athetosis: □ yes   □ no                                       □ unknown   
If yes, specify: ______ 
              Debut: □ at onset   □ later, Date _ _/_ _/_ _    □ unknown 
                                                  Present at last follow up: □ yes □ no               □ unknown    
 Other motor disorders: □ yes   □ no                               □ unknown   
If yes, specify: _________ 
                                                 Debut: □ at onset   □ later, Date _ _/_ _/_ _      □ unknown 
             Present at last follow up: □ yes □ no                 □ unknown    
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 Other: □ yes   □ no                                                                     □ unknown   
If yes, specify: 
 Hearing impairment: □ yes   □ no                                  □ unknown   
If yes, specify: _________ 
                    Debut: □ at onset   □ later, Date_ _/ _ _/_ _    □ unknown 
                    Present at last follow up: □ yes □ no               □ unknown    
Sensorineural hearing loss: □ yes   □ no                        □ unknown   
If yes, specify: _________ 
               Debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
               Present at last follow up: □ yes □ no              □ unknown    
 Peripheral neuropathy: □ yes   □ no                               □ unknown   
      If yes, specify: _________ 
               Debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
               Present at last follow up: □ yes □ no               □ unknown    
 Fatigue: □ yes   □ no                                                      □ unknown   
If yes, specify: _________ 
                                                    Debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
               Present at last follow up: □ yes □ no               □ unknown    
 Exertional myalgia: □ yes   □ no                                    □ unknown   
      If yes, specify: _________ 
               Debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
               Present at last follow up: □ yes □ no               □ unknown    
 Other not otherwise specified: □ yes   □                         □ unknown   
If yes, specify: _________ 
               Debut: □ at onset   □ later, Date _ _/_ _/_ _    □ unknown 
               Present at last follow up: □ yes □ no               □ unknown    
 
 Psychomotor developmental disorders: □ yes   □ no                              □ unknown   
If yes, specify: 
 Global developmental delay:     □ yes   □ no                             □ unknown   
If no, specify:  
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 Neuropsychiatric and cognitive disorders: □ yes   □ no                      □ unknown   
If yes, specify:  
 Depression: □ yes   □ no                                                          □ unknown   
If yes,          debut: □ at onset   □ later, Date _ _/_ _/_ _        □   unknown 
                    Present at last follow up: □ yes □ no                   □ unknown  
 Psychosis: □ yes   □ no                                                            □ unknown   
If yes,          debut: □ at onset   □ later, Date _ _/_ _/_ _         □   unknown 
                    Present at last follow up: □ yes □ no                   □ unknown  
 
 Dementia: □ yes   □ no                                                              □ unknown   
If yes,          debut: □ at onset   □ later, Date _ _/_ _/_ _        □   unknown 
                    Present at last follow up : □ yes □ no                 □ unknown  
 
 Visual hallucination: □ yes   □ no                                         □ unknown   
If yes,          debut: □ at onset   □ later, Date _ _/_ _/_ _        □  unknown 
                    Present at last follow up : □ yes □ no                 □ unknown  
 
 Mental retardation: □ yes   □ no                                               □ unknown   
If yes,          debut: □ at onset   □ later, Date _ _/_ _/_ _       □   unknown 
                    WPPSI III test□ performed  □ not performed   □ unknown    
                    WISC IV test  □ performed  □ not performed   □ unknown    
                    WAIS   test     □ performed  □ not performed   □ unknown    
                    WMS    test     □ performed  □ not performed   □ unknown   
  
 Ophthalmological disorders: □ yes   □ no                                        □ unknown   
If yes, specify: 
 Ptosis:            □ yes   □ no                                                       □ unknown   
If yes,          symmetry: □ bilateral  □unilateral                   □ unknown  
                    Debut: □ at onset   □ later, Date _ _/_ _/_ _     □   unknown 
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 Progressive external ophthalmoplegia: □ yes   □ no        □ unknown   
     If yes,     symmetry: □bilateral □unilateral                    □unknown 
                    Debut: □ at onset   □ later, Date _ _/_ _/_ _    □   unknown 
                    Present at last follow up: □ yes □ no               □ unknown  
 Cataract: □ yes   □ no                                                       □ unknown   
    If yes,      symmetry: □bilateral □unilateral                     □unknown 
                    Debut: □ at onset   □ later, Date _ _/_ _/_ _    □   unknown 
                    Present at last follow up: □ yes □ no               □ unknown  
 
 Strabismus: □ yes   □ no                                                  □ unknown   
   If yes,        debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
                          Present at last follow up : □ yes □ no             □ unknown  
 Nystagmus: □ yes   □ no                                                  □ unknown   
   If yes,        debut: □ at onset   □ later, Date_ _/ _ _/_ _   □  unknown 
                     Present at last follow up: □ yes □ no             □ unknown  
 Pigmentary retinopathy: □ yes   □ no                               □ unknown   
   If yes,       specify:____________ 
                                            Debut: □ at onset   □ later, Date_ _/ _ _/_ _    □ unknown 
                    Present at last follow up: □ yes □ no               □ unknown  
 Visual impairment: □ yes   □ no                                      □ unknown   
If yes,       debut: □ at onset   □ later, Date _ _/_ _/_ _    □ unknown 
                 Present at last follow up: □ yes □ no              □ unknown  
 Cortical blindness : □ yes   □ no                                      □ unknown   
If yes,        debut: □ at onset   □ later, Date _ _/_ _/_ _   □ unknown 
                  Present at last follow up: □ yes □ no             □ unknown  
 
 Other ophthalmological disorder: □ yes   □ no               □ unknown   
If yes,         specify:____________  
                   Debut: □ at onset   □ later, Date _ _/_ _/_ _ □ unknown 
                   State at last follow up: □ yes □ no                □ unknown  
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 Cardiac disorders: □ yes   □ no                                                       □ unknown   
If yes, specify:  
 Cardiomyopathy: □ yes   □ no                                            □ unknown   
If yes, specify;    
□ Dilated cardiomyopathy  
      Debut: □ at onset   □ later, Date _ _/_ _/_ _                 □ unknown 
      Present at last follow up: □ yes □ no                            □ unknown 
□ Hypertrophic cardiomyopathy  
      Debut: □ at onset   □ later, Date _ _/_ _/_ _                 □ unknown 
      Present at last follow up: □ yes □ no                            □ unknown 
 
□ Hypertension 
      Debut: □ at onset   □ later, Date _ _/_ _/_ _                □ unknown 
      Present at last follow up: □ yes □ no                           □ unknown 
□ Other____  
     Debut: □ at onset   □ later, Date _ _/_ _/_ _                 □ unknown 
     Present at last follow up: □ yes □ no                            □ unknown 
□Unknown  
     Debut: □ at onset   □ later, Date _ _/_ _/_ _                  □ unknown 
     Present at last follow up: □ yes □ no                             □ unknown 
 
 Other cardiac disorder: specify _________________ 
             If yes,         Specify: ____________  
                   Debut: □ at onset   □ later, Date _ _/ _ _/_ _               □ unknown 
                   Present at last follow up: □ yes □ no                           □ unknown 
 Endocrine disorders: □ yes   □ no                                                   □ unknown   
If yes, specify:  
 Diabetes mellitus type 1: □ yes   □ no                                □ unknown   
If yes, specify: _________ 
      Debut: □ at onset   □ later, Date _ _/_ _/_ _                  □ unknown 
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 Diabetes mellitus type 2: □ yes   □ no                                 □ unknown   
        If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _/_ _                   □ unknown 
            Present at last follow up: □ yes □ no                              □ unknown    
 Exocrine pancreatic insufficiency: □ yes   □ no                   □ unknown                                  
      If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _/_ _                  □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 Hypogonadism: □ yes   □ no                                               □ unknown   
          If yes, specify: _________ 
      Debut: □ at onset   □ later, Date _ _/_ _ / _ _                □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 
 Delayed puberty: □ yes   □ no                                             □ unknown   
If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown    
 Irregular menses: □ yes   □ no      □     not applicable      □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                 □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 Repeated miscarriage: □ yes   □ no  □ not applicable        □ unknown                                               
If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                 □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 
 Adrenal insufficiency: □ yes   □ no                                    □ unknown   
If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                 □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 Growth hormone deficiency: □ yes   □ no                           □ unknown   
      If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                 □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
The mitochondrial & neurogenetics research group, Bergen, Norway. CRF-POLG study   13 
 
 
 Other endocrine disorder : □ yes   □ no                               □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                 □ unknown 
            Present at last follow up: □ yes □ no                             □ unknown    
 Gastrointestinal and nutritional disorders: □ yes   □ no                  □ unknown   
If yes, specify: 
 Failure to thrive: □ yes   □ no                                             □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown  
 
 
 Feeding difficulties: □ yes   □ no                                        □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ / _ _               □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown    
 Gastrointestinal dysmotility: □ yes   □ no                           □ unknown   
      If yes, specify: _________ 
           Debut: □ at onset   □ later, Date _ _/_ _ /_ _           □ unknown 
           Present at last follow up: □ yes □ no                       □ unknown 
 Chronic diarrhoea :                    □ yes   □ no                      □ unknown   
                             If yes, specify: _________ 
          Debut: □ at onset   □ later, Date _ _/_ _ /_ _            □ unknown 
          Present at last follow up:           □ yes □ no             □ unknown 
 Vomiting: □ yes   □ no                                                        □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _        □ unknown 
            Present at last follow up: □ yes □ no                    □ unknown    
 Other gastrointestinal disorder : □ yes   □ no                    □ unknown   
       If yes, specify: _________ 
          Debut: □ at onset   □ later, Date _ _/_ _ /_ _            □ unknown 
                                 Present at last follow up: □ yes □ no                        □ unknown    
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 Hematologic disorders: □ yes   □ no                                             □ unknown   
If yes, specify: 
 Anaemia: □ yes   □ no                                                       □ unknown   
       If yes, specify:  □Microcytic  □ Macrocytic  □ normocytic □ unknown  
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _               □ unknown 
            Present at last follow up: □ yes □ no                           □ unknown    
 Leukopenia: □ yes   □ no                                                   □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown    
 Thrombocytopenia: □ yes   □ no                                        □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _               □ unknown 
            Present at last follow up: □ yes □ no                           □ unknown    
 Other haematological disorders: □ yes   □ no                    □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _               □ unknown 
            Present at last follow up: □ yes □ no                           □ unknown    
 Other disorders: □ yes   □ no      □ unknown    
If yes, specify: 
 Renal disorder: □ yes   □ no                                           □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                           □ unknown    
 Hepatic disorder : □ yes   □ no                                       □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown    
 Respiratory disorder : □ yes   □ no                                 □ unknown   
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _               □ unknown 
            Present at last follow up: □ yes □ no                           □ unknown    
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 Other disorder not otherwise specified: □ yes   □ no     □ unknown                                           
       If yes, specify: _________ 
            Debut: □ at onset   □ later, Date _ _/_ _ /_ _                □ unknown 
            Present at last follow up: □ yes □ no                            □ unknown    
  Smoking : □ yes   □ no                                                   □ unknown                                           
                         If yes, specify: □ at onset   □ later, Date _ _/_ _/_ _          □ unknown 
                          Smoking at last follow up: □ yes □ no                              □ unknown    
 
                                    Disease Course 
 
 Has the patient experienced acute exacerbation(s)/relapse(s): 
□ yes                   □ no                                                                    □ unknown    
 Main cause : □ infection   □ side effect of medication   
□ other, specify_____________                                         □unknown  
 Treatment required :  
□ outpatient care   □hospitalization  □ICU                      □ unknown  
 Type(s) of exacerbation symptoms:  □Motor □seizures  
□ cognitive      □other, specify_______.                        □unknown  
 
                                   Survival Status  
 
 Last known status : □alive  □deceased □ unknown/ lost to follow up  
If deceased, specify  
 Date of death _ _ / _ _ / _ _ _ _  ( dd/ mm/yyyy) 
 Cause of death : □Status epilepticus □Liver failure □Multi-organ failure 
□Sepsis □other____________________ □ unknown  
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                                  Laboratory Findings  
 
 Respiratory chain enzyme activity : □ assayed  □ not assayed/unknown  
If assayed, Date: _ _/ _ _/ _ _       □normal          □abnormal  
If abnormal, specify: _________________________________ 
 
 In muscle Ref. Range In liver  Ref. Range In Fibroblast Ref. Range 
Complex I       
Complex 
II+III 
      
Complex IV       
Complex V       
 
 Blue native gel perform : □ yes □ no                                            □ unknown   
If yes, specify: _________________________________________  
 At onset : 
 Absolute values in blood/ serum:  
 pH: ____ ,    ref. __-__   □normal   □not taken/ unknown  
 Base excess: :    ____ ,   ref. __-__ □normal   □abnormal               
□not taken/ unknown 
 Lactate:              ____  mmol/L,    ref. __-__   □normal □abnormal           
□not taken/ unknown 
 Pyruvate:             ____ mmol/L,   ref. __-__   □normal □abnormal           
□not taken/ unknown 
 
 Glucose : ____ mmol/L,  ref. __-__   □normal   □abnormal                       
□not taken/ unknown 
 
 Creatinine kinase: ____ IU/L,  ref. __-__  □normal  □abnormal           
□not taken/ unknown  
 Albumin:              ____ g/L,  ref. __-__   □normal  □abnormal           
□not taken/ unknown 
 ASAT:                  ____ IU/L ,  ref. __-__   □normal  □abnormal          
□not taken/ unknown 
 ALAT:                  ____IU/L  ,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
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 GGT  :                  ____ IU/L,  ref. __-__   □normal   □abnormal           
□not taken/ unknown 
 Hb:                       ____ g/dL,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
 MCV                       ____ fl,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
 Vit B12                       ____ pmol/L,  ref. __-__   □normal   
□abnormal         □not taken/ unknown 
 Folate                 ____ nmol/L,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
  
 Ferritin:                ____ microgram/L,  ref. __-__   □normal  
□abnormal          □not taken/ unknown  
 Iron:                      ____ mircromol/L,  ref. __-__   □normal   
□abnormal          □not taken/ unknown 
 Absolute values in CSF:   
 Lactate:               ____ mmol/L,  ref. __-__    □normal    □abnormal          
□not taken/ unknown 
 Pyruvate:             ____ mmol/L,  ref. __-__   □normal    □abnormal          
□not taken/ unknown 
 Albumin:             ____ mg/L,  ref. __-__   □normal     □abnormal          
□not taken/ unknown 
 Protein:               ____ g/L,  ref. __-__    □normal     □abnormal            
□not taken/ unknown 
 
 Most abnormal values noted over disease course: 
 Absolute values in blood/ serum : 
 pH:                      ____ ,  ref. __-__ , date: _ _/ _ _/ _ _   □normal    
□abnormal           □not taken/ unknown  
 Base excess: :      ____ ,  ref. __-__   , date: _ _/ _ _/ _ _ □normal   
□abnormal            □not taken/ unknown 
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 Lactate:               ____ mmol/L,  ref. __-__  , date: _ _/ _ _/ _ _  
□normal   □abnormal           □not taken/ unknown 
 Pyruvate:             ____ mmol/L ,  ref. __-__   , date: _ _/ _ _/ _ _ 
□normal   □abnormal           □not taken/ unknown 
 Glucose : ____ mmol/L,  ref. __-__               , date: _ _/ _ _/ _ _  
□normal   □abnormal                       □not taken/ unknown 
 
 Creatinine kinase: ____ IU/L,  ref. __-__  , date: _ _/ _ _/ _ _ □normal   
□abnormal          □not taken/ unknown  
 Albumin:       ____ g/L,  ref. __-__         , date: _ _/ _ _/ _ _  □normal    
□abnormal           □not taken/ unknown 
 ASAT:           ____ IU/L,  ref. __-__         , date: _ _/ _ _/ _ _  □normal    
□abnormal           □not taken/ unknown 
 ALAT: :         ____ IU/L,  ref. __-__         , date: _ _/ _ _/ _ _ □normal    
□abnormal           □not taken/ unknown 
 Hb:                 ____ g/dL,  ref. __-__        , date: _ _/ _ _/ _ _ □normal     
□abnormal           □not taken/ unknown 
 MCV                       ____ fL,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
 Vit 12                       ____ pmol/L,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
 Folate                    ____ nmol/L,  ref. __-__   □normal   □abnormal         
□not taken/ unknown 
  
 Ferritin:          ____ mircromol/L,  ref. __-__        , date: _ _/ _ _/ _ _ 
□normal     □abnormal          □not taken/ unknown  
 Iron:               ____ mircromol/L,  ref. __-__        , date: _ _/ _ _/ _ _ 
□normal     □abnormal            □not taken/ unknown 
 Absolute values in CSF: 
 Lactate:          ____ mmol/L,  ref. __-__       , date: _ _/ _ _/ _ _ 
□normal      □abnormal           □not taken/ unknown 
 Pyruvate:       ____ mmol/L,  ref. __-__       , date: _ _/ _ _/ _ _ 
□normal      □abnormal            □not taken/ unknown 
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 Albumin:       ____ mg/L,  ref. __-__       , date: _ _/ _ _/ _ _ □normal      
□abnormal            □not taken/ unknown 
 Protein:          ____ g/L,  ref. __-__      , date: _ _/ _ _/ _ _ □normal      
□abnormal              □not taken/ unknown 
 
 Pathological total or free carnitine: □ yes   □ no                □ unknown   
If yes, date of the test : _ _/ _ _/_ _, absolute value:_____  ref: __-___ 
 Pathological acyl carnitine:              □ yes   □ no                □ unknown   





 Muscle pathology abnormality: □ yes   □ no                      □ unknown / not perform 
If yes 








Excess lipid  
□ yes   □ no                          
□ unknown 
□ yes □ no                          
□ unknown 
□ yes □ no                          
□ unknown 
□ yes □ no                          
□ unknown 
 
 Other Specify:_______________________________________________ 
 Electron microscopy performed : □ yes   □ no       □ unknown / not perform 
 If yes , specify __________________________________________ 
 Liver pathology abnormality: □ yes   □ no                          □ unknown / not perform 
If yes 
 Date: _ _/  _ _/ _ _ ( dd/ mm/yy)  
 Specify:_______________________________________________ 
 
 Pathological EEG: □ yes   □ no                                           □ unknown / not perform 
If yes: 
 Date_ _/  _ _/_ _ ( dd/mm/yy)  
 Finding _____________________________________ 
 Epi.activity: □ yes   □ no                                          □ unknown 
If yes :  □frontal□ parietal □temporal □occipital □ multifocal □unknown 
 Repeated examination: □ no □progression□ no clear change       □unknown 
 Pathological EMG: □ yes   □ no                                         □ unknown / not perform 
If yes: 
 Date _ _ /_ _/_ _ ( dd/mm/yy)  
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 Finding:  □ Myopathic □ neuropathic □ other ______   □ unknown  
 
 Pathological nerve conduction : □ yes   □ no                      □ unknown / not perform 
If yes: 
 Date _ _/_ _/_ _ ( dd/ mm/yy)  
 Finding: □ axonal □demyelinating □combination □other____  □ unknown 
 
      • Pathological VER  : □ yes   □ no                      □ unknown / not perform 
            If yes: Date _ _/_ _/_ _ ( dd/ mm/yy)  
 
      • Pathological ERG  : □ yes   □ no                      □ unknown / not perform 




                                      MtDNA Findings 
 
 Genetic analysis method :  
□ Long PCR    □ Real Time PCR     □Other, specify _________ 
 
Tissue mtDNA deletion (YES / 
NO / % if available) 
mtDNA depletion (YES / 
NO / % if available) 
Skeletal muscle □yes□ no,           %: □yes □no;              %: 
Liver □yes□no,            %: □yes□no,              %: 
Brain □yes□no,            %: □yes□no,              %: 
Other □yes□no,             %: □yes□no,               %: 
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                                         Imaging  
 
 First cerebral MRI : date :_ _/  _ _/ _ _ (dd/ mm/yy) 
      Finding:  □ yes   □ no                      □ unknown / not perform 
If abnormal please complete the below MRI registration form :  
Region                        Signal abnormality  Atrophy  
□Putamen □ No signal abnormality  □ no atrophy 
□ bilateral  
□ unilateral  
T1:□increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 











□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 





      □decreased 
□ bilateral 
□ unilateral 
□Pons □ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 





    □decreased 
□ bilateral 
□ unilateral 
□medulla □ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 





    □decreased 
□ bilateral 
□ unilateral 
□vermis □ No signal abnormality □ no atrophy 
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T1:□ increased 





    □decreased 
□ bilateral 
□ unilateral 




□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 












□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 










□ No signal abnormality □ no atrophy 
□ bilateral  
□ unilateral 
T1:□ increased 




    □decreased 
□ bilateral 
□ unilateral 
□ other   
 
 2nd cerebral MRI: □ performed                                        □ unknown / not perform 
If performed,  date :_ _/  _ _/ _ _ (dd/ mm/yy) 
  □ progression,__________ □ regression,__________ □ no changed 
Other notes :  
 
 
If this is the first abnormal MRI please complete the MRI registration form  
 Last cerebral MR: □ performed                                       □ unknown / not perform 
If performed,  date :_ _/  _ _/ _ _ ( dd/mm/yy) 
  □ progression,__________ □ regression,__________ □ no changed 
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 MRI of the thigh: □ performed                                        □ unknown / not perform 
If performed,  date : _ _/ _ _/ _ _ ( dd/mm/yy) 
Specify:______________________ 
 MRS: □ yes   □ no                                                         □ unknown / not perform 
If normal , date :_ _/  _ _/ _ _ ( dd/ mm/yy) 
If abnormal , date :_ _/  _ _ / _ _ ( dd/ mm/yy) 
□ elevated lactate                        region ____________ 
□ elevated choline                       region ____________ 
□ elevated succinate                   region _____________ 
□ decreased NAA                       region _____________ 
□ other, specify _______            region _____________ 
 CT finding 1st  CT : □ normal    □ abnormal                    □ unknown / not perform  
If normal, date : _ _/_ _/ _ _ ( dd/ mm/yy) 
If abnormal, date : _ _/ _ _ / _ _ ( dd/ mm/yy) 
□ calcifications                             region ____________ 
□ high attenuation                        region _____________ 
□ low attenuation                         region _____________ 





























                                      Treatment  
 
 Antiepileptic treatment: □ yes   □ no                      □ unknown 
□ single antiepileptic drug, specify ___________ date started : _ _/ _ _/_ _ 
□ combination of antiepileptic drugs , specify ____________________________ 
□ antiepileptic drugs used with no effect : _____, _______,_______,______,_____ 
□ valproate , date started: _ _/ _ _/_ _.  
□ on-going antiepileptic drugs:  effect : □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________  
 Ketogenic diet : □ yes   □ no                      □ unknown 
If yes : date started : _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect : □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Coenzyme Q10: □ yes   □ no                      □ unknown 
If yes : date started : _ _/ _ _ / _ _ ( dd/mm/yy)  
□ on-going:  effect : □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Thiamine: □ yes   □ no                      □ unknown 
If yes : date started : _ _/ _ _ / _ _ ( dd/mm/yy)  
□ on-going:  effect : □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Nicotinamide: □ yes   □ no                      □ unknown 
If yes : date started : _ _ / _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect : □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Riboflavin: □ yes   □ no                      □ unknown 
If yes: date started : _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect: □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Carnitine: □ yes   □ no                      □ unknown 
If yes: date started : _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect: □ no apparent □positive □ unknown 
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□ discontinued, reason(s):______________________________ 
 Folic acid: □ yes   □ no                      □ unknown 
If yes: date started : _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect: □ no apparent □positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Antidiabetic treatment: □ yes   □ no                      □ unknown 
If yes: date started: _ _/ _ _ / _ _ ( dd/ mm/yy)  
□on-going:  effect: □ no apparent □positive □ unknown 
□discontinued, reason(s):______________________________ 
 Oral contraceptive: □ yes   □ no                      □ unknown 
If yes: date started: _ _/ _ _ / _ _ ( dd/ mm/yy)  
 
 
 Other: □ yes   □ no                      □ unknown 
If yes: date started: _ _ / _ _ ( mm/yy)  
□on-going:  effect: □ no apparent □positive □ unknown 
□discontinued, reason(s):______________________________ 
 Other: □ yes   □ no                      □ unknown 
If yes: date started: _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect: □ no apparent □ positive □ unknown 
□ discontinued, reason(s):______________________________ 
 Other: □ yes   □ no                      □ unknown 
If yes: date started: _ _/ _ _ / _ _ ( dd/ mm/yy)  
□ on-going:  effect: □ no apparent □ positive □ unknown 
□ discontinued, reason(s):______________________________ 
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                               Investigator signature  
 
I have carefully checked all the data recorded in the present case report form and I confirm 
that they are true, complete and accurate to the best of my knowledge.  
 
Investigator name:        ________________________________ 
 
Registration completed:   yes □                                          no □ 
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Summary
Background: Variants in POLG are one of the most common causes of
inherited mitochondrial disease. Phenotypic classification of POLG disease
has evolved haphazardly making it complicated and difficult to implement in
everyday clinical practise. The aim of our study was to simplify the classifica-
tion and facilitate better clinical recognition.
Methods: A multinational, retrospective study using data from 155 patients
with POLG variants recruited from seven European countries.
Results: We describe the spectrum of clinical features associated with POLG
variants in the largest known cohort of patients. While clinical features
clearly form a continuum, stratifying patients simply according to age of
onset—onset prior to age 12 years; onset between 12 and 40 years and onset
after the age of 40 years, permitted us to identify clear phenotypic and prog-
nostic differences. Prior to 12 years of age, liver involvement (87%), seizures
(84%), and feeding difficulties (84%) were the major features. For those with
onset between 12 and 40 years, ataxia (90%), peripheral neuropathy (84%),
and seizures (71%) predominated, while for those with onset over 40 years,
ptosis (95%), progressive external ophthalmoplegia (89%), and ataxia (58%)
were the major clinical features. The earlier the onset the worse the progno-
sis. Patients with epilepsy and those with compound heterozygous variants
carried significantly worse prognosis.
Conclusion: Based on our data, we propose a simplified POLG disease classi-
fication, which can be used to guide diagnostic investigations and predict dis-
ease course.
KEYWORD S
Alpers syndrome, epilepsy, mitochondrial disease, POLG, stroke-like episodes
1 | INTRODUCTION
Mitochondria are intracellular organelles found in almost
all human cells. Their key function is the production of
adenosine triphosphate through the process of oxidative
phosphorylation performed by the mitochondrial respira-
tory chain (MRC). The MRC comprises more than 90 pro-
teins organised into five complexes (I-V). Mitochondrial
DNA (mtDNA) codes for 13 proteins while the remaining
proteins are encoded by nuclear DNA.1 The enzyme that
replicates and repairs mtDNA, polymerase γ,2 is a
heterotrimer comprising a catalytic subunit (POLG) and
two accessory subunits (POLG2). Mutations in POLG
(OMIM * 174763), the nuclear gene encoding the cata-
lytic subunit, interfere with mtDNA maintenance.2,3
Variants in POLG are the single most common cause of
inherited mitochondrial disease.4 The first POLG variant
associated with disease was described in a family with auto-
somal dominant progressive external ophthalmoplegia
(PEO5), but since then, more than 190 disease-causing
variants have been identified (http://tools.niehs.nih.giv/
polg). POLG variants are associated with a wide spectrum
of overlapping phenotypes ranging from devastating fatal
neonatal disease to a mild late onset disease with myopa-
thy and PEO. A summary of the major POLG-related
phenotypes reported in the literature4,6-22 is provided in
Table 1.
The clinical features of POLG disease are extremely
heterogeneous making early clinical recognition chal-
lenging. The increasing numbers of terms that have been
used to describe the clinical phenotypes (Table 1) have
added to this confusion.
The clinical reports published so far were based
on small numbers of patients and did not describe
the clinical spectrum through the whole life span.
Longitudinal studies describing the natural history of
the disease in a large cohort of patients are still
lacking.
2 HIKMAT ET AL.
In this study, we aimed to describe the natural history
of POLG disease in the largest cohort of patients with
confirmed POLG variants, focusing on the clinical fea-
tures and the biomarkers which may predict the long-
term prognosis. We aimed to provide a simpler clinical
classification to facilitate early clinical recognition of
patients with POLG disease.
2 | METHODS
2.1 | Study design, population, and
data collection
We performed a multinational, retrospective study of
patients from 12 centres in seven European countries:
TABLE 1 Summary of the major syndromes associated with POLG mutations reported in the literature
Phenotype nomenclatures
(reference) Major clinical features Age of onset









3 Alpers syndrome4,13,14 Synonym of AHS As in AHS
4 Alpers-Huttenlocher like21 Synonym of AHS As in AHS
5 Infantile hepatocerebral syndrome9 Includes AHS and MCHS Neonate, infancy,
childhood
6 Infantile mitochondrial DNA depletion
syndrome19
Includes both AHS and MCHS Infancy, childhood
7 Leigh like19 Psychomotor retardation, hypotonia, extrapyramidal
dysfunction, symmetrical hyperintensities on T2





Severe gastrointestinal dysmotility, encephalopathy,
ptosis ophthalmoplegia, peripheral neuropathy
Childhood, adolescence
adulthood
9 Myoclonus, epilepsy, myopathy, and
sensory ataxia (MEMSA)4
Epilepsy, myopathy, ataxia, liver dysfunction,
headache and stroke-like episodes
Adolescence, adulthood
10 Spinocerebellar ataxia with epilepsy
(SCAE)4,7
Now incorporated under MEMSA umbrella As in MEMSA
11 Mitochondrial spinocerebellar ataxia
with epilepsy (MSCAE)6
Now incorporated under MEMSA umbrella As in MEMSA
12 Ataxia neuropathy spectrum (ANS)4,7 Ataxia, neuropathy, psychiatric symptoms, cognitive
impairment, epilepsy, and ophthalmoplegia
Adolescent and adult
13 Mitochondrial recessive ataxia
syndrome (MIRAS)10
Now incorporated under ANS umbrella As in ANS
14 Sensory ataxia neuropathy dysarthria
and ophthalmoplegia (SANDO)4
Now incorporated under ANS umbrella As in ANS
15 Mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like
episodes (MELAS) like phenotype23




Recessive Charcot-Marie tooth like12 Axonal polyneuropathy, muscle weakness, wasting,
tremor nystagmus, dysarthria, dysmetria, and
dysdiadochokinesis.
Adult
17 Parkinsonism8,16 Tremor, rigidity, hypo/bradykinesia, balance
disturbance
Adult
18 Autosomal recessive progressive
external ophthalmoplegia (arPEO)5,7
Ptosis, ophthalmoparesis, may be associated with
ataxia and myopathy
Adult, elderly
19 Autosomal dominant progressive
external ophthalmoplegia (adPEO)5,7
Ptosis, ophthalmoparesis, myopathy, neuropathy,
ataxia
Adult-elderly
20 Chronic progressive external
ophthalmoplegia plus(CPEO+)7
Synonym of adPEO Adult-elderly
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Norway (Haukeland University Hospital, Oslo University
Hospital, St. Olav's Hospital and University Hospital of
Northern Norway); United Kingdom (Great Ormond
Street Hospital, London); Sweden (Centre for Inherited
Metabolic Diseases, Karolinska University Hospital,
Stockholm and The Queen Silvia Children's Hospital,
University of Gothenburg); Denmark (Department of
Clinical Genetics, Copenhagen University Hospital); Fin-
land (Children's Hospital, Helsinki University Hospital
and Clinic for Children and Adolescents, Oulu University
Hospital); Netherlands (Department of Genetics and Cell
Biology, Maastricht University, Maastricht); and Spain
(Sant Joan de Déu Children's Hospital, Barcelona).
Patients diagnosed and followed at the participating cen-
tres were considered eligible if they had recessive disease
and confirmed biallelic pathogenic/likely pathogenic
POLG variants or dominant disease and heterozygous
confirmed pathogenic variants. Data entry was completed
in December 2017.
Detailed clinical, biochemical, muscle biopsy, neuro-
physiological, neuroimaging, and genetic data were
obtained by using an electronic-case report form com-
pleted by the responsible investigator(s) at each centre
and reviewed by the study-principal investigator (O.H.).
The date of disease onset was defined by the date of
the first symptom(s) requiring medical evaluation. End of
follow up was defined as the date of the patient's last visit
to the follow-up centre or death. Available longitudinal
data, both at disease onset and later during the disease
course, were collected. Liver involvement was defined by
the presence of two or more of the following parameters
in at least two different time points; elevated aspartate
aminotransferase, gamma-glutamyltransferase, bilirubin
or ammonia, low serum albumin, or pathological histo-
logical findings of liver biopsy. The presence of anaemia
and abnormal cerebrospinal fluid (CSF) protein and/or
albumin was identified as described in previous publica-
tions.13,14,24 We use the recent International League
Against Epilepsy (ILAE) classification25 for seizure
classification.
2.2 | Data and statistical analysis
Detailed descriptive data analysis was performed on the
entire study cohort using SPSS (Statistical Package of
Social Sciences), Version 23.0. A two sided P value less
than .05 was considered to be statistically significant.
Mosaic plots was performed by using R (The R founda-
tion for statistical computing), version 3.6.1.
In order to simplify the clinical classification patients
were grouped according to the age of disease onset into
three groups: (a) those with disease onset prior to the age
of 12 years (before puberty), (b) those with disease onset
between 12 and 40 years, and (c) those with disease onset
after the age of 40 years. The age of onset of each individ-
ual symptom was recorded and classified according to
these three defined age-groups. Correspondence analysis
was performed to examine the relationship between two
variables (groups of patients who were classified
according to the age of onset as described and the age of
onset of each individual symptom) graphically in a multi-
dimensional space; this allowed examination of the clus-
tering of symptoms around each age group. Further,
mosaic plots was performed to study the differences
between the above mentioned groups. The study cohort
was also classified according to the presence or absence
of epilepsy, regardless the age of onset.
For survival analysis, the end-point was time to death
which was defined as the time in months from the date
of disease onset to the date of death. Univariate survival
analysis was performed using log-rank test (Kaplan-




One hundred and fifty-five patients, (males n = 76 [49%],
females n = 79 [51%]) with confirmed pathogenic POLG
variants were identified. Seventy-six were diagnosed in
Norway, 44 in Sweden, 19 in the United Kingdom,
8 in Finland, 5 in Denmark, 2 in The Netherlands, and
1 in Spain. The majority of patients were Northern
European (n = 146), while three patients were from Iraq,
two from Cyprus and one from Croatia, Pakistan, Spain,
and the United Arab Emirates.
3.2 | Major clinical features
Median age at disease onset for the whole study cohort
was 10 years (range: birth—71 years). Disease onset prior
to the age of 12 years occurred in 54% (n = 83/155),
between 12 and 40 years of age in 34% (n = 53/155), and
after the age of 40 years in 12% (n = 19/155) had. Disease
debut was apparently spontaneous in 113/155 (73%),
followed an infectious illness in 32/155 (21%) and not
clearly reported in 10/155 (6%) of the patients.
Neurological (90%, n = 139/155), ophthalmological
(74%, n = 112/151), and gastrointestinal symptoms (63%,
n = 92/146) were the most predominant clinical features.
Epilepsy was reported in 69% (n = 107/155), with focal
and focal evolving to bilateral tonic-clonic seizures being
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Seizure 107/154 (69%) 73/106 (69%) 33/106 (31%)
Focal 94/102 (92%) 60/91 (66%) 31/91 (34%)
Focal evolving to bilateral tonic-clonic 85/100 (85%) 43/85 (51%) 42/85 (49%)
Myoclonic 73/98 (74%) 26/71 (37%) 45/71 (63%)
Epilepsia partialis continua 52/91 (57%) 15/52 (29%) 37/52 (71%)
Convulsive status epilepticus 79/101 (78%) 30/78 (38%) 48/78 (62%)
Othersa 11/80 (14%) 5/10 (50%) 5/10 (50%)
Ataxia 87/138 (63%) 53/85 (62%) 32/85 (38%)
Hypotonia 68/135 (50%) 50/66 (76%) 16/66 (24%)
Limb weakness 89/125 (71%) 33/83 (40%) 50/83 (60%)
Migraine-like headache 52/143 (36%) 38/52 (73%) 14/52 (27%)
Peripheral neuropathy 65/123 (53%) 23/63 (36%) 40/63 (64%)
Sensorineural hearing loss 16/146 (11%) 9/16 (56%) 7/16 (44%)
2. Ophthalmological
Ptosis 51/149 (34%) 28/49 (57%) 21/49 (43%)
Progressive external ophthalmoplegia 56/146 (38%) 24/56 (43%) 32/56 (57%)
Nystagmus 55/146 (38%) 29/53 (55%) 24/53 (45%)
Cataract 11/148 (7%) 2/9 (22%) 7/9 (78%)
Cortical blindness 32/111 (29%) 17/29 (59%) 12/29 (41%)
Pigmentary retinopathy 3/140 (2%) 1/2 (50%) 1/2 (50%)
3. Gastrointestinal
Feeding difficulties 75/145 (52%) 36/73 (49%) 37/73 (51%)
Vomiting 52/137 (38%) 31/49 (63%) 18/49 (37%)
Chronic diarrhoea 8/136 (6%) 2/8 (25%) 6/8 (75%)
Liver involvement 95/151 (64%) 35/93 (38%) 58/93 (62%)
Othersb 7/128 (5%) 2/7 (29%) 5/7 (71%)
4. Endocrinological
Diabetes mellitus type 1 1/151 (1%) 0/1 (0%) 1/1 (100%)
Diabetes mellitus type 2 2/151 (1%) 2/2 (100%) 0/2 (0%)
Adrenal insufficiency 2/151 (1%) 1/2 (50%) 1/2 (50%)
Growth hormone deficiency 2/147 (1%) 1/2 (50%) 1/2 (50%)
Othersc 3/140 (2%) 0/3 (0%) 3/3 (100%)
5. Others
Anaemia 77/136 (57%) 20/77 (26%) 57/77 (74%)
Renal disordersd 13/149 (8%) 3/12 (25%) 9/12 (75%)
Respiratory disorderse 18/149 (12%) 5/18 (28%) 13/18 (72%)
aOne infantile spasms, eight absence, one atonic seizure, and one non convulsive status epilepticus.
bOne Coeliac disease, one constipation, one paralytic ileus, one acute colon necrosis, one gastrointestinal bleeding, one colitis, and one milk protein
intolerance.
cOne hypothyroidism, one hypoparathyroidism, and one pseudo hypoparathyroidism.
dSeven renal tubular acidosis, five renal failure, and one renal stone.
eTwo asthma, one chest deformity, two recurrent chest infections, two sleep apnoea, elven hypoventilation/respiratory insufficiency.
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the most common seizure types (92%, n = 94/102). Ataxia
(63%, n = 87/138), peripheral neuropathy (53%,
n = 65/123), and hypotonia (50%, n = 68/135) were fre-
quently reported. Nystagmus (38%, n = 55/146), PEO
(38%, n = 56/146), and ptosis (34%, n = 51/149) were the
most commonly reported ophthalmological features.
Liver involvement was identified in 64% (n = 96/151) of
the patients. More than half of the study cohort had feed-
ing difficulties (52%, n = 75/145), regardless of the age of
onset. A detailed description of the clinical features is
provided in Table 2.
3.3 | Age-related clinical features
We found clear evidence that the clinical features of
POLG disease form a continuum (Figure 1) rather than
distinct phenotypes (Table 1). Nevertheless, by grouping
the patients into three groups according to the age of
onset (early, juvenile/adult, and late onset groups), we
could identify clear phenotypic and prognostic differ-
ences (Table 3). To confirm this finding, correspondence
analysis was performed and demonstrated clear cluster-
ing of the symptoms around the three different age
groups as illustrated in Figure S1. Further, mosaic plots
showed there was a statistically significance differences
in the phenotypes between the above mentioned groups
(Figure S2).
3.4 | Laboratory, muscle biopsy, and
neurophysiological findings
The percentage of those with raised lactate in serum and
CSF at disease onset was 35% (n = 29/84) and 40%
(n = 19/47), respectively. Abnormal elevated CSF protein
at disease onset was reported in 68% (n = 44/68) of
patients. In muscle biopsies, the presence of ragged-red
fibres, COX-negative fibres, and abnormal respiratory
chain activities was reported in fewer than the half of
those who had been investigated (Table S1).
Electroencephalogram recordings showed that
approximately half (54%, n = 58/107) of patients with
epilepsy had epileptiform activities over the occipital
lobes. Abnormal nerve conduction was observed in 70%










Age at onset in years
FIGURE 1 Age of onset of each
individual symptom in patients with
POLG disease. Range I, Median. PEO,
progressive external ophthalmoplegia
TABLE 3 The onset of symptoms according to three age
groups
Symptoms
<12 years 12–40 years >40 years
83/155 (54%) 53/155 (34%) 19/155 (12%)
Seizures 69/82 (84%) 37/52 (71%) 1/19 (5%)
Ataxia 30/67 (45%) 46/51 (90%) 11/19 (58%)
Hypotonia 57/72 (79%) 9/44 (20%) 2/18 (11%)
Stroke-like
episodes
26/73 (36%) 26/48 (54%) None (0%)
Peripheral
neuropathy
17/57 (30%) 38/45 (84%) 10/18 (65%)
Migraine-like
headache
14/52 (27%) 36/52 (69%) 2/52 (4%)
Feeding
difficulties
58/69 (84%) 13/47 (28%) 4/18 (22%)
Liver
involvement
71/82 (87%) 23/49 (47%) 2/19 (11%)
Anaemia 49/71 (69%) 25/45 (56%) 3/16 (19%)
Ptosis 12/78 (15%) 21/50 (42%) 18/19 (95%)
PEO 7/83 (8%) 32/48 (67%) 17/19 (89%)
Survival time
in months
19 (0.5–600) 151 (4–487) 191 (17–336)
Median (Range)
Abbreviation: PEO, progressive external ophthalmoplegia.
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(n = 43/61) of the individuals, the majority of those (81%,
n = 35/43) had axonal neuropathy. None had a pure
demyelinating neuropathy (Table S1).
3.5 | Neuroimaging findings
General cerebral atrophy (59%, n = 35/59) and cortical
focal lesions (54%, n = 59/108) manifesting as T2/FLAIR
hyperintensities affecting cortical and subcortical areas
were the most frequently reported magnetic resonance
imaging (MRI) abnormalities in the study group as a
whole. These imaging findings were more prevalent in
patients with epilepsy compared to those without epi-
lepsy. A detailed description of MRI findings is provided
in Table S2.
3.6 | Genetic findings
POLG variant(s) for each case were identified either by
targeted variant analysis for specific common variants
(c.1399G>C, p.Ala467Thr and c.2243G>C, p.Trp748Ser)
or by sequence analysis of all coding regions of the POLG
gene. All POLG variants identified in this study are illus-
trated in igure S3 and the individual mutation results are
available on request.
A total of 41 different POLG variants were identified in
the 155 individuals described in this study. Ninety patients
had compound heterozygous variants, 59 had homozygous
variants, and 6 patients had a heterozygous variant
associated with autosomal dominant disease, mainly auto-
somal dominant progressive external ophthalmoplegia. The
majority (n = 58/83) of patients with early onset disease
(before the age of 12 years) had compound heterozygous
pathogenic POLG variants (regardless of the variant types).
The opposite was found in those with juvenile/adult
onset disease in whom the majority (n = 32/52) had
homozygous pathogenic variants. Frequency data for the
homozygous variant c.1399G>C, p.(Ala467Thr, com-
pound heterozygous variants c.1399G>C, p.(Ala467Thr)/
c.2243G>C, p.(Trp748Ser), and the homozygous variant
c.2243G>C, p.(Trp748Ser) for each of the three age
groups are provided in Table S3.
3.7 | Survival analysis
Of the155 patients, 61 were alive at the time of data anal-
ysis and one had been lost to follow-up. Median age at
death was 7.4 years (range 1 month to 91 years). The
main cause of death was liver failure (32%, n = 30/93),
followed by infection/sepsis (20%, n = 19/93), multi-
organ failure (19%, n = 18/93), status epilepticus (14%,
n = 13/93), one suicidal death. The cause of death was
unknown in 13% (n = 12/93) of the individuals.
Further analysis showed that median survival time
from disease onset to death was 19 months (range
0.5-600 months, interquartile range [IQR] 111) for those
with disease onset prior to the age 12 years, 151 months
(range 4-487, IQR 255) for those with disease onset
between 12 and 40 years, and 191 months (range 17-336,
FIGURE 2 Survival analysis. A, Kaplan-Meier curve comparing survival of those with seizures and those without seizures and showed
those with seizures carried significantly worse survival. B, Kaplan-Meier curve comparing survival of those with homozygous variants and
those with compound heterozygous POLG variants and showed those with compound heterozygous variants carried significantly worse
survival
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IQR 101) for those with disease onset after the age of
40 years.
The presence of epilepsy was associated with signifi-
cantly worse survival (P < .001), and the median survival
time from seizure onset to death was 37 months (range
<1-487). Survival analysis also showed that patients with
pathogenic compound heterozygous POLG variants had
significantly (P < .001) worse survival compared to those
with pathogenic homozygous variants, regardless of spe-
cific variant types (Figure 2). Further analysis showed
that survival after the onset of seizures in those with early
onset disease was significantly worse than those who
developed seizures as part of juvenile/adult onset disease.
Further, patients who developed liver involvement
showed a significantly worse survival than those without
liver impairment (Figure S4).
4 | DISCUSSION
We present the detailed description of 155 patients with
confirmed pathogenic POLG variants focusing on the
clinical features, but including laboratory, genetic, and
neuroimaging findings. As far as we can ascertain, this is
the largest cohort of patients with POLG disease so far
described. In addition to the descriptive element, we have
also analysed factors, which may predict the prognosis.
We defined the age of onset of each individual symp-
tom and our data confirms that POLG disease comprises
a continuum of clinical features rather than a set of sepa-
rate clinical identities (Figure 1). Apart from PEO/ptosis,
all other symptoms could start from infancy to adult-
hood. While hypotonia and feeding difficulties in infants
are likely due to different pathological processes than
these features appearing in adults, seizures, peripheral
neuropathy, ataxia, muscle weakness, and hepatic distur-
bance have a similar basis and all could present at any
age. PEO/ptosis starts later and appears mainly in
patients with dominantly inherited disease or in those
with juvenile/early adult onset disease who do not
develop epilepsy or, less often, survive despite it. Stroke-
like episodes appear to start slightly later than most other
features. This may reflect the nature of the process26,27
namely that these represent prolonged seizure activity or
status epilepticus.
If we look at the median ages of onset, instead of
looking at the age range, we do see a tendency for the
features to cluster according to age. We, therefore,
reanalysed the data using different age groups. Based on
these findings, we found that the clinical spectrum of
POLG disease was best described by grouping patients
into three categories of early, juvenile/adult, and late
onset. Early onset disease was classified as beginning
prior to the age of 12 years. In these patients, liver
involvement, feeding difficulties, seizures, hypotonia, and
muscle weakness were the most dominant/important
clinical features and this group had the worst prognosis.
The juvenile/adult onset form (12-40 years of age) was
characterised by peripheral neuropathy, ataxia, seizures,
stroke-like episodes and, in patients with longer survival,
PEO. This group carried a better prognosis than the early
onset group. Late onset disease (after the age of 40 years)
was characterised by ptosis and PEO, with additional fea-
tures such as peripheral neuropathy ataxia and muscle
weakness occurring frequently. This group had the best
prognosis. Thus, while the clinical features associated
with POLG variants can present at any age, age of disease
onset provides both clues to the diagnosis and informa-
tion about the outcome (Table 3).
The most frequently reported neurological features,
included seizures, ataxia, and peripheral neuropathy.
Focal evolving to bilateral tonic-clonic seizures were the
most common seizure types, with epileptiform activities
predominantly seen in occipital regions. These findings
are consistent with previous reports (8,10,13-15,28,29), how-
ever, our results also showed that seizures were the most
predominant clinical feature in patients with early onset
disease (<12 years), common in those with juvenile/adult
onset (12-40 years), but infrequent in those with late
onset disease (>40 years). Ataxia, peripheral neuropathy,
and migraine-like headache were most predominant in
individuals with juvenile/adult onset disease, although
reported in both early and late onset disease. Ptosis and
PEO were common in late onset disease as reported
previously,22 however our data showed that the onset of
ptosis and PEO occurred in all age groups. The onset of
gastrointestinal features such as feeding difficulties and
liver involvement occurred at any age, but was predomi-
nantly seen in patients with early onset disease.
Demographic data showed that more than half of the
individuals included in this study had onset during child-
hood (prior to the age of 12), and the incidence of the dis-
ease decreased with age. Contrary to previous
publications,9,15 which demonstrate some male predomi-
nance, we observed no gender difference.
Survival analysis demonstrated a clear correlation
between the age of disease onset and the survival time;
earlier onset was associated with worse prognosis
(Table 3). Further analysis showed that the presence of
epilepsy was significantly associated with worse progno-
sis regardless of the age of disease onset, and individuals
harbouring compound heterozygous POLG variants had
worse prognosis compared to those with homozygous
variants.
Our study showed that laboratory investigations which
are commonly used in the initial diagnostic work-up of
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mitochondrial disorders, for example, raised blood and
CSF lactate, the presence of ragged-red/COX-negative
fibres and abnormal respiratory chain activities in the skel-
etal muscle have low diagnostic sensitivity, being present
in fewer than 50% of the individuals. As we showed in a
previous publication,24 elevated CSF protein was the most
sensitive (68%, n = 44/65) laboratory diagnostic biomarker
at disease onset.
The majority of the patients included in this study were
of Northern European descent; thus, a possible limitation
of this study is that it might not be possible to extrapolate
our findings to other ethnic groups. However, we provide
detailed description of all the known phenotypes associ-
ated with POLG disease related to more than 40 different
POLG variants. Moreover, there is little evidence in the lit-
erature of marked ethnic differences in phenotypic
expression of POLG disease. Based on the diverse geno-
typic background of our population, we consider that the
findings of our study are relevant to patients with POLG
disease, regardless of the ethnic background.
A simple and robust clinical classification is the cor-
nerstone of early diagnosis. Such a classification, together
with diagnostic investigations, should facilitate easy rec-
ognition of the disease and be useful for both experts and
physicians with limited experience of the field. Current
nomenclature describing the phenotypic spectrum of
POLG disease (Table 1) is complicated and includes over-
lapping clinical syndromes. This makes implementation
in everyday clinical practice difficult. A clear and accu-
rate classification that describes the full spectrum of dis-
ease taking account of age-related features is essential
not only for optimal management, but also for research
FIGURE 3 Diagnosing POLG disease; clinical suspicion and relevant investigations according to the age of onset. While we have
shown that POLG clinical features form a continuum, but it is also clear that age plays a role in which features predominate. Based on our
age groups, we can see clear clinical patterns and these will dictate which investigations are appropriate and useful. For example, in the
older age category, PEO and ataxia dominate the clinical spectrum and in these cases one can choose either to screen the known genes or to
take a muscle biopsy which give both structural clues (COX negative fibres) and the possibility to examine mtDNA (for multiple deletions).
We also see that the typical occipital epilepsy occurs in the younger two categories and it is in these that MRI imaging also provides
important clues. Peripheral neuropathy occurs in all age groups. In earlier studies, we showed that elevated CSF protein can be helpful, for
example in a child with epilepsy and focal MRI changes it can be an important indicator of poor prognosis. a: Direct POLG gene sequence
analysis is recommended to confirm the diagnosis in a case of strong clinical suspicion. b: Absence of these findings does not exclude the
diagnosis of POLG disease. c: targeted variant analysis for the most common variants (p. Ala467Thr and p.Trp748Ser) can be performed first
in juvenile and late onset disease, whole POLG gene sequence analysis is recommended for all early onset disease and those with strong
clinical suspicion of POLG disease regardless of the age of onset. CSF, cerebrospinal fluid; RRF, ragged-red fibres; PEO, progressive external
ophthalmoplegia; P. neuropathy, peripheral neuropathy; SLE, stroke- like episodes
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and, when treatments become available, for use in clini-
cal trials.
We provide a robust and simplified clinical classifica-
tion based on data from the largest cohort of patients
with POLG disease published to date. This classification
highlights three distinct age groups and within these
groups the major clinical features. Earlier classifications
of POLG disease have focused primarily on phenotypic
elements; for example, the presence of ataxia with or
without myoclonus or epilepsy has variously been
referred to as SANDO, ANS, or MIRAS/MSCAE. Early
onset diseases have been separated into Alpers or MCHS
or Leigh-like syndromes. The presence of mtDNA deple-
tion has also been used to define POLG related disease
although the presence of this is known to be tissue
dependent and depletion in brain and liver is found in
both young and older patients. We feel that these pheno-
typic labels create an unnecessarily complicated classifi-
cation. Age alone appears robust enough to delineate the
important features of POLG disease such that we would
recommend simplifying classification to early onset, juve-
nile onset and late onset POLG disease. The algorithm
(Figure 3) shows how recognition of these key clinical
features could be used to direct clinical investigation in
the different age groups.
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Supplementary table 1: Summary of the diagnostic investigations 
 
Diagnostic investigations Number of patients with pathological findings 
 At onset  Later  
1-Blood    
Raised lactate  29/84(35%) 63/98(64%) 
Raised creatine kinase 5/88(6%) 21/73(29%) 
Low albumin 18/83(22%) 66/95(69%) 
Raised aspartate aminotransferase 33/107(31%) 83/124(67%) 
Raised alanine aminotransferase  29/120(24%) 89/137(65%) 
2-Cerebrospinal fluid    
Raised lactate  19/47(40%) 26/39(67%) 
Raised albumin 14/23(61%) 12/18(67%) 
Raised protein  44/65(68%) 22/30(73%) 
 Number of patients with pathological findings 
 during the disease course  
3- Muscle biopsy    
Pathological finding in general 61/103(59%) 
Ragged-Red fibres 22/85(26%) 
COX-negative fibres 37/87(45%) 
Excessive lipid accumulation  22/82(27%) 
Abnormal respiratory chain activities  25/54(46%) 
4-EEG findings -epileptiform activities  
Frontal lobe 18/107(17%) 
Parietal lobe 25/107(23%) 
Temporal lobe 33/107(31%) 
Occipital lobe 58/107(54%) 
Multifocal  15/107(14%) 
5- EMG   
Pathological findings in general  25/55(45%) 
Myopathic  6/25(24%) 
Neuropathic  18/25(72%) 
Non-specified  1/25(4%) 
6-Nerve conduction study   
Pathological findings in general  43/61(70%) 
Axonal  35/43(81%) 
Demyelinating 0/43(0%) 
Combined 5/43(12%) 







Supplementary table 2: Neuroimaging findings 
 
Cerebral MRI 
findings General  Epilepsy+ Epilepsy - 
Cortical focal lesions 59/108(54%) 54/80(68%) 2/29(7%) 
Generalised 
cerebral atrophy 35/59(59%) 14/27(52%) 3/8(38%) 
Putamen lesions  4/106(4%) 3/77(4%) 1/29(3%) 
Caudate nucleus 
lesions 6/104(6%) 6/75(8%) 0/29(0%) 
Thalamus lesions 44/109(4%) 39/80(49%) 5/29(17%) 
Pons lesions 10/105(10%) 4/76(5%) 6/29(21%) 
White matter lesions 8/105(8%) 6/79(8%) 2/29(7%) 
Vermis lesions 4/103(4%) 3/74(4%) 1/29(3%) 
Dentate nucleus 
lesions  5/103(5%) 3/74(4%) 2/29(7%)  
MRI: Magnetic Resonance Imaging, Epilepsy+: Subjects with epilepsy. Epilepsy -: subjects without 
epilepsy 
 
Supplementary table 3: The frequency of Homozygous variant c.1399G>C, 
p.(Ala467Thr, Hetrozygous variants c.1399G>C, p.(Ala467Thr)/ c.2243G>C, 
p.(Trp748Ser) and Homozygous variant  c.2243G>C, p.(Trp748Ser) according to 








POLG variants Early onset 
( < 12 years ) 
Juvenile/adult onset 
(12-40 years ) 
Late onset 
(> 40 years ) 
Homozygous variant 
c.1399G>C, p.(Ala467Thr) 
 7 % (no.6 /83) 13%( no. 7/52) 5% (no.1/19)  
Hetrozygous variants  
c.1399G>C, p.(Ala467Thr)/ 
c.2243G>C, p.(Trp748Ser) 
6% (no.5/83) 23%( no.12/52) 5% (no. 1/19)  
Homozygous variant  
c.2243G>C, p.(Trp748Ser) 






Supplementary Figure 1: Correspondence analysis showed clustering of 
variable symptoms around the three different age groups (onset prior to the 
age of 12 years, onset between the age of 12-40 years and onset after the age 















Supplementary Figure 2 (A-K): Moisac plots shows there are a statistically 
significant differences between the 3 age groups ( those with onset before 12 
years, onset 12-40 years and onset after 40 years of age ). 











C) Hypotonia (P-Value= 1.2032e-08) 
 













E) Peripheral neuropathy ( P-value = 1.7285e-06) 
 


















































Supplementary figure 3: Genetic findings (variants) of patients with POLG 








Supplementary figure 4 (A-B): Survival analysis.  
3- A: Kaplan-Meier curve comparing survival after the onset of seizure in those with early 
onset disease and those with juvenile/ adult onset ,and showed those with early onset had 
significantly worse survival 
 
3-B:  Kaplan-Meier curve comparing survival of those with hepatopathy and those without, 
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